<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6d187c8c-fbc5-468e-a094-bf16c4f09d4c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use OMVOH safely and effectively. See full prescribing information for OMVOH.<br/>
      <br/>OMVOH (mirikizumab-mrkz) injection, for intravenous or subcutaneous use<br/>Initial U.S. Approval: 2023
</title>
   <effectiveTime value="20250403"/>
   <setId root="472cbe04-263e-433d-9a0f-58c1b50b715a"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="006421325" root="1.3.6.1.4.1.519.1"/>
            <name>Eli Lilly and Company</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="37f2b152-50b4-4d9f-9a7b-2a489f3bcf01"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250403"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-7575" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Omvoh</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mirikizumab-mrkz</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="20" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mirikizumab</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.4"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="B22547B95K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>trisodium citrate dihydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.4"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>anhydrous citric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="8.8"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="15"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-7575-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231026"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231026"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-8011" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Omvoh</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mirikizumab-mrkz</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mirikizumab</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.9"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine monohydrochloride monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="33"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.9"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-8011-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-8011-27" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20231026"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-8011-61" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-8011-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250403"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20231026"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-8870" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Omvoh</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mirikizumab-mrkz</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mirikizumab</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.9"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine monohydrochloride monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="33"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.9"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-8870-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="2"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-8870-27" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240429"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240429"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-7717" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Omvoh</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mirikizumab-mrkz</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-7717-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-7717-61" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C96974" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0002-8011" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Omvoh</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mirikizumab-mrkz</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="100" unit="mg"/>
                                    <denominator value="1" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>mirikizumab</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.1"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine monohydrochloride monohydrate</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="33"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mannitol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.3"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>polysorbate 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="2.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>sodium chloride</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>water</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-8011-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0002-3116" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Omvoh</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mirikizumab-mrkz</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="100" unit="mg"/>
                                    <denominator value="1" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>mirikizumab</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.1"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine monohydrochloride monohydrate</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="33"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mannitol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.3"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>polysorbate 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="2.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>sodium chloride</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>water</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="mL"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-3116-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="mL"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-7722" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Omvoh</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mirikizumab-mrkz</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0002-7722-11" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 1: Convenience Kit of Co-Package"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0002-8870" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Omvoh</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mirikizumab-mrkz</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="100" unit="mg"/>
                                    <denominator value="1" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>mirikizumab</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.1"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine monohydrochloride monohydrate</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="33"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mannitol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.3"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>polysorbate 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="2.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>sodium chloride</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>water</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator unit="1" value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-8870-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="2" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0002-1442" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Omvoh</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>mirikizumab-mrkz</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="100" unit="mg"/>
                                    <denominator value="1" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>mirikizumab</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.1"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>histidine monohydrochloride monohydrate</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="33"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mannitol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="0.3"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>polysorbate 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="2.9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>sodium chloride</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>water</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="2" unit="mL"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-1442-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <approval>
                                 <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0002-3116" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Omvoh</name>
                        <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>mirikizumab-mrkz</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="100" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mirikizumab</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Z7HVY03PHP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>mirikizumab</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.1"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.9"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>histidine monohydrochloride monohydrate</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="33"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>mannitol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="0.3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>polysorbate 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <quantity>
                              <numerator unit="mg" value="2.9"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="2"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43202" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0002-3116-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250403"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102836" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 3: Prefilled Biologic Delivery Device/System (syringe, patch, etc.)"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250403"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761279" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="41af3181-5a70-46f6-b8f7-57dc7da2db60"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="86.750%" align="left"/>
                           <col width="13.250%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Indications and Usage (<linkHtml href="#s2">1</linkHtml>)
</td>
                                 <td align="right" valign="top">1/2025
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Dosage and Administration (<linkHtml href="#s11">2.4</linkHtml>, <linkHtml href="#s16">2.5</linkHtml>, <linkHtml href="#s18">2.6</linkHtml>)
</td>
                                 <td align="right" valign="top">1/2025
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="08fe0d0a-948e-44fb-a73e-6afa6fdffa47"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>OMVOH is indicated for the treatment of:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>moderately to severely active ulcerative colitis in adults.
</item>
                     <item>
                        <content styleCode="xmChange"/>moderately to severely active Crohn's disease in adults.
</item>
                  </list>
               </text>
               <effectiveTime value="20250115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>OMVOH<sup>TM</sup> is an interleukin-23 antagonist indicated for the treatment of:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>moderately to severely active ulcerative colitis in adults (<linkHtml href="#s2">1</linkHtml>)
</item>
                           <item>moderately to severely active Crohn's disease in adults (<linkHtml href="#s2">1</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="e2526054-e175-4b4c-ae84-4c8721fe4f33"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20250122"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Prior to Treatment Initiation</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Evaluate patients for tuberculosis (TB) infection. (<linkHtml href="#s4">2.1</linkHtml>, <linkHtml href="#s24">5.3</linkHtml>)
</item>
                           <item>Obtain liver enzymes and bilirubin levels. (<linkHtml href="#s4">2.1</linkHtml>, <linkHtml href="#s25">5.4</linkHtml>)
</item>
                           <item>Complete all age-appropriate vaccinations according to current immunization guidelines. (<linkHtml href="#s4">2.1</linkHtml>, <linkHtml href="#s26">5.5</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Important Administration Instructions</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The 200 mg/2 mL prefilled pen and prefilled syringe are only for maintenance treatment of Crohn's disease. (<linkHtml href="#s5">2.2</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage for Ulcerative Colitis</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Induction Dosage</content>: Week 0, Week 4, and Week 8: Infuse 300 mg intravenously over at least 30 minutes. (<linkHtml href="#s6">2.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Maintenance Dosage</content>: Week 12 and every 4 weeks thereafter: Inject 200 mg subcutaneously (given as two consecutive injections of 100 mg each). (<linkHtml href="#s6">2.3</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage for Crohn's Disease</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Induction Dosage</content>: Week 0, Week 4, and Week 8: Infuse 900 mg intravenously over at least 90 minutes. (<linkHtml href="#s11">2.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Maintenance Dosage</content>: Week 12 and every 4 weeks thereafter: Inject 300 mg subcutaneously (given as two consecutive injections of 100 mg and 200 mg in any order). (<linkHtml href="#s11">2.4</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Preparation and Administration Instructions</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>See the full prescribing information for preparation, administration and storage information for intravenous infusion and subcutaneous injection. (<linkHtml href="#s6">2.3</linkHtml>, <linkHtml href="#s11">2.4</linkHtml>, <linkHtml href="#s16">2.5</linkHtml>, <linkHtml href="#s18">2.6</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s4">
                     <id root="501d453e-fe06-4c95-95ae-3b245a17fa58"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Evaluations and Immunizations Prior to Treatment Initiation
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with OMVOH <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.3</linkHtml>)]</content>.
</item>
                           <item>Obtain liver enzymes and bilirubin levels prior to initiating treatment with OMVOH <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.4</linkHtml>)]</content>.
</item>
                           <item>Complete all age-appropriate vaccinations according to current immunization guidelines <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s26">5.5</linkHtml>)]</content>.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s5">
                     <id root="a46f2aaa-afee-4f22-a949-637b0074a528"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Important Administration Instructions
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The 200 mg/2 mL prefilled pen and prefilled syringe are only for maintenance treatment of Crohn's disease.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="3955cb59-c29b-4bc2-a3ca-5edb02b47830"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage for Ulcerative Colitis
</title>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s7">
                           <id root="c132ed0f-7637-4f5e-95c3-506c1757ac07"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Induction Dosage</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s8">
                                 <id root="4fab6d44-5c15-4642-8f32-82c33eca0a41"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics underline">Week 0, Week 4, and Week 8:</content> Infuse 300 mg intravenously over at least 30 minutes <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s16">2.5</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s9">
                           <id root="6abdbc7a-74d4-4f4b-b54a-dd194a1bedb7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Maintenance Dosage</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s10">
                                 <id root="75095458-f620-496a-81cb-2494dc455fe9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics underline">Week 12 and every 4 weeks thereafter:</content> Inject 200 mg subcutaneously (given as two consecutive injections of 100 mg each) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s16">2.5</linkHtml>) and How Supplied/Storage and Handling (<linkHtml href="#s80">16</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="4002b8f0-fb9e-4b63-87b7-7302e1983782"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage for Crohn's Disease
</title>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s12">
                           <id root="9231be0c-ff8f-42b5-a429-0f8ee1e9ac7d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange"/>
                                 <content styleCode="underline">Induction Dosage</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s13">
                                 <id root="d6e55129-396e-4860-a650-8b15f0d80680"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="xmChange"/>
                                       <content styleCode="italics underline">Week 0, Week 4, and Week 8:</content> Infuse 900 mg intravenously over at least 90 minutes <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s16">2.5</linkHtml>)].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s14">
                           <id root="296b675a-b32e-421e-8fa1-6657cfb8a318"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="xmChange"/>
                                 <content styleCode="underline">Maintenance Dosage</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s15">
                                 <id root="f46d61b2-35cf-4651-ab69-6f3d386f0da8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="xmChange"/>
                                       <content styleCode="italics underline">Week 12 and every 4 weeks thereafter:</content> Inject 300 mg subcutaneously (given as two consecutive injections of 100 mg and 200 mg in any order) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s16">2.5</linkHtml>) and How Supplied/Storage and Handling (<linkHtml href="#s80">16</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="785ce85b-8bfd-42b0-8aa8-66e1067a717c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Preparation and Administration Instructions for Intravenous Infusion
</title>
                     <text>
                        <list listType="ordered" styleCode="Arabic">
                           <item>OMVOH for intravenous use is intended for administration by a healthcare provider using aseptic technique.
</item>
                           <item>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be a clear to opalescent, colorless to slightly yellow to slightly brown solution, and free of visible particles. Do not use OMVOH if it is cloudy or there are visible particles.
</item>
                           <item>
                              <content styleCode="xmChange"/>Prior to intravenous administration, determine the dose needed based on the patient's indication (see <linkHtml href="#t1">Table 1</linkHtml> below). For Crohn's disease, discard 45 mL of the infusion bag prior to adding vial contents. Withdraw the required amount of solution from the vial(s) using a 18 gauge to 21 gauge needle and transfer to an infusion bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection (see <linkHtml href="#t1">Table 1</linkHtml> below). Do not mix with other drugs. Do not dilute or infuse through the same intravenous line with other solutions.<table ID="t1" width="100%">
                                 <caption>Table 1: Intravenous Induction Dose and Volume of Diluent Required
</caption>
                                 <col width="18.455%" align="left"/>
                                 <col width="23.081%" align="left"/>
                                 <col width="23.081%" align="left"/>
                                 <col width="35.384%" align="left"/>
                                 <tbody>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="xmChange"/>
                                          <content styleCode="bold">Indication</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Intravenous Induction Dose</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Number of OMVOH 300mg/15mL vials needed</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Volume of
</content>
                                          <br/>
                                          <content styleCode="bold">0.9% Sodium Chloride or<br/>5% Dextrose Injection</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="xmChange"/>Ulcerative colitis
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">300 mg
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">50 mL, 100 mL, or 250 mL
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                          <content styleCode="xmChange"/>Crohn's disease
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">900 mg
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">3
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">100 mL or 250 mL
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </item>
                           <item>Gently invert the infusion bag to mix the contents. Do not shake the prepared infusion bag.
</item>
                           <item>Connect the intravenous administration set (infusion line) to the prepared infusion bag and prime the line.
</item>
                           <item>Infuse the diluted solution intravenously over a period of at least 30 minutes for the 300 mg dose; at least 90 minutes for the 900 mg dose. If stored refrigerated, allow the diluted solution in the infusion bag to warm to room temperature prior to the start of the intravenous infusion.
</item>
                           <item>At the end of the infusion, flush the line with 0.9% Sodium Chloride Injection or 5% Dextrose Injection.<list listType="unordered" styleCode="Disc">
                                 <item>Administer the flush at the same infusion rate as used for OMVOH administration.
</item>
                                 <item>The time required to flush OMVOH solution from the infusion line is in addition to the minimum 30-minute infusion time.
</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s17">
                           <id root="45da79e9-4b7c-48ae-b79a-af85b3946856"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Storage of Diluted Solution</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Start the infusion immediately after preparation. If not used immediately, store the diluted infusion solution in the refrigerator at 2°C to 8°C (36°F to 46°F). Use the diluted infusion solution within 48 total hours, of which not more than 5 hours are permitted at non-refrigerated temperatures not to exceed 25°C (77°F), starting from the time of vial puncture.
</item>
                                 <item>Keep drug product away from direct heat or light. Do not freeze the diluted solution in the prepared infusion bag.
</item>
                              </list>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="3b210555-80a0-49c6-994b-1aaf28363a02"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Preparation and Administration Instructions for Subcutaneous Injection
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="xmChange"/>A full maintenance dose will require 2 prefilled pens or 2 prefilled syringes given as two consecutive injections, in any order.
</item>
                           <item>OMVOH is intended for use under the guidance and supervision of a healthcare professional. Patients may self-inject OMVOH after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of OMVOH according to the “Instructions for Use”, included with the packaged product.
</item>
                           <item>
                              <content styleCode="xmChange"/>Before injection, remove OMVOH prefilled pens or OMVOH prefilled syringes from the refrigerator and leave at room temperature for 30 minutes if using the carton containing 100 mg/mL + 100 mg/mL or 45 minutes if using the carton containing 200 mg/2 mL + 100 mg/mL.
</item>
                           <item>
                              <content styleCode="xmChange"/>Do not shake the prefilled pens or prefilled syringes.
</item>
                           <item>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The solution should be a clear to opalescent, colorless to slightly yellow to slightly brown solution, and free of visible particles. Do not use OMVOH if it is cloudy, discolored, or there are visible particles.
</item>
                           <item>Sites for injection include the abdomen, thigh, and back of the upper arm. Instruct patients to inject in a different location every time. For example, if the first injection was in the abdomen, administer the second injection (to complete a full dose) in another area of the abdomen, or upper arm, or thigh. Administration of OMVOH in the back of upper arm may only be performed by another person.
</item>
                           <item>Do not inject into areas where the skin is tender, bruised, erythematous, or indurated.
</item>
                           <item>OMVOH does not contain preservatives; therefore, discard any unused product. Do not reuse.
</item>
                           <item>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing every 4 weeks.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20250122"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s19">
               <id root="f995d471-1425-441f-9e7d-f826ff3144c5"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>OMVOH is a clear to opalescent, colorless to slightly yellow to slightly brown solution available as:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Intravenous Infusion: <br/>Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
</item>
                     <item>Subcutaneous Use: <br/>Injection: 100 mg/mL solution in a single-dose prefilled pen<br/>Injection: 100 mg/mL solution in a single-dose prefilled syringe<br/>Injection: 200 mg/2 mL solution in a single-dose prefilled pen<br/>Injection: 200 mg/2 mL (100 mg/mL) solution in a single-dose prefilled syringe
</item>
                  </list>
               </text>
               <effectiveTime value="20250115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Intravenous Infusion</content> (<linkHtml href="#s19">3</linkHtml>)
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Subcutaneous Injection</content> (<linkHtml href="#s19">3</linkHtml>):
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Injection: 100 mg/mL solution in a single-dose prefilled pen
</item>
                           <item>Injection: 100 mg/mL solution in a single-dose prefilled syringe
</item>
                           <item>Injection: 200 mg/2 mL solution in a single-dose prefilled pen
</item>
                           <item>Injection: 200 mg/2 mL (100 mg/mL) solution in a single-dose prefilled syringe
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s20">
               <id root="453c6165-29a9-4efc-9435-eadd272af356"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>OMVOH is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.1</linkHtml>)]</content>.
</paragraph>
               </text>
               <effectiveTime value="20250115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>History of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients. (<linkHtml href="#s20">4</linkHtml>, <linkHtml href="#s22">5.1</linkHtml>).
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s21">
               <id root="847b9258-6e98-49cc-a22e-c190ebd634e1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20250116"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Hypersensitivity Reactions</content>: Serious hypersensitivity reactions, including anaphylaxis and infusion-related reactions, have been reported. If a severe hypersensitivity reaction occurs, discontinue and initiate appropriate treatment. (<linkHtml href="#s22">5.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Infections</content>: OMVOH may increase the risk of infection. Do not initiate treatment with OMVOH in patients with a clinically important active infection until the infection resolves or is adequately treated. If a serious infection develops, do not administer OMVOH until the infection resolves. (<linkHtml href="#s23">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Tuberculosis</content>: Do not administer OMVOH to patients with active TB infection. Monitor patients receiving OMVOH for signs and symptoms of active TB during and after treatment. (<linkHtml href="#s24">5.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Drug-induced liver injury has been reported. Monitor liver enzymes and bilirubin levels at baseline and for at least 24 weeks of treatment and thereafter according to routine patient management. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. (<linkHtml href="#s25">5.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="underline">Immunizations</content>: Avoid use of live vaccines. (<linkHtml href="#s26">5.5</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s22">
                     <id root="51a4a367-3c70-4811-85c9-b6a938286806"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions
</title>
                     <text>
                        <paragraph>Serious hypersensitivity reactions, including anaphylaxis during intravenous infusion, have been reported with OMVOH administration. Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s28">6.1</linkHtml>)]</content>. If a severe hypersensitivity reaction occurs, discontinue OMVOH immediately and initiate appropriate treatment.
</paragraph>
                     </text>
                     <effectiveTime value="20250116"/>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="71a5cea9-1b85-4632-a97a-8a724854b2bb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Infections
</title>
                     <text>
                        <paragraph>OMVOH may increase the risk of infection <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#s28">6.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Do not initiate treatment with OMVOH in patients with a clinically important active infection until the infection resolves or is adequately treated.
</paragraph>
                        <paragraph>In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing OMVOH. Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer OMVOH until the infection resolves.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s24">
                     <id root="a6f741a8-3ef0-4a73-a071-76057ffbd814"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Tuberculosis
</title>
                     <text>
                        <paragraph>Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with OMVOH.
</paragraph>
                        <paragraph>Do not administer OMVOH to patients with active TB infection. Initiate treatment of latent TB prior to administering OMVOH. Consider anti-TB therapy prior to initiation of OMVOH in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after OMVOH treatment.
</paragraph>
                        <paragraph>In clinical trials, subjects were excluded if they had evidence of active TB, a past history of active TB, or were diagnosed with latent TB at screening.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s25">
                     <id root="18ce00fe-f0ca-449a-9dcb-2d702b78062b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Hepatotoxicity
</title>
                     <text>
                        <paragraph>A case of drug-induced liver injury (alanine aminotransferase [ALT] 18x the upper limit of normal (ULN), aspartate aminotransferase [AST] 10x ULN, and total bilirubin 2.4x ULN) in conjunction with pruritus was reported in a clinical trial subject following a longer than recommended induction regimen. OMVOH was discontinued. Liver test abnormalities eventually returned to baseline.
</paragraph>
                        <paragraph>Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment. Monitor thereafter according to routine patient management.
</paragraph>
                        <paragraph>Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.
</paragraph>
                     </text>
                     <effectiveTime value="20250116"/>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="4c84530a-0766-43e9-847c-b0cd042e310b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Immunizations
</title>
                     <text>
                        <paragraph>Avoid use of live vaccines in patients treated with OMVOH. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy with OMVOH, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or non-live vaccines in patients treated with OMVOH.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="7ae3042a-80b7-480c-bdb3-20c4518a4816"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following topics are also discussed in detail in the Warnings and Precautions section:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.1</linkHtml>)]</content>
                     </item>
                     <item>Infections <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.2</linkHtml>)]</content>
                     </item>
                     <item>Tuberculosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.3</linkHtml>)]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.4</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250115"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Ulcerative colitis (≥2%)</content>:<list listType="unordered" styleCode="Circle">
                                 <item>
                                    <content styleCode="italics">Induction</content>: upper respiratory tract infections and arthralgia. (<linkHtml href="#s28">6.1</linkHtml>)
</item>
                                 <item>
                                    <content styleCode="italics">Maintenance:</content> upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection. (<linkHtml href="#s28">6.1</linkHtml>)
</item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Crohn's disease (≥5%)</content>: upper respiratory tract infections, injection site reactions, headache, arthralgia, and elevated liver tests (<linkHtml href="#s28">6.1</linkHtml>)
</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s28">
                     <id root="90e9e264-7b3e-4c35-b3a3-f151245f3be6"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s29">
                           <id root="ccc9f3ea-8962-453e-9c59-9cab0e47dc18"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Ulcerative Colitis</content>
                              </paragraph>
                              <paragraph>OMVOH was studied up to 12 weeks in subjects with moderately to severely active ulcerative colitis in a randomized, double-blind, placebo-controlled induction study (UC-1). In subjects who responded to induction therapy in UC-1, long term safety up to 52 weeks was evaluated in a randomized, double-blind, placebo-controlled maintenance study (UC-2) and a long-term extension study <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s70">14.1</linkHtml>)]</content>.
</paragraph>
                              <paragraph>In the induction study (UC-1), 1279 subjects were enrolled of whom 958 received OMVOH 300 mg administered as an intravenous infusion at Weeks 0, 4, and 8. In the maintenance study (UC-2), 581 subjects were enrolled of whom 389 received OMVOH 200 mg administered as a subcutaneous injection every 4 weeks.
</paragraph>
                              <paragraph>
                                 <linkHtml href="#t2">Table 2</linkHtml> summarizes the adverse reactions reported in at least 2% of subjects and at a higher frequency than placebo during UC-1.
</paragraph>
                              <table ID="t2" width="100%">
                                 <caption>Table 2: Adverse Reactions<sup>a</sup> in Subjects with Ulcerative Colitis through Week 12 in a Placebo-Controlled Induction Study (UC-1)
</caption>
                                 <col width="33.333%" align="left"/>
                                 <col width="33.400%" align="left"/>
                                 <col width="33.267%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Reported in at least 2% of subjects and at a higher frequency than placebo.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> OMVOH 300 mg as an intravenous infusion at Weeks 0, 4, and 8.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> Upper respiratory tract infections includes related terms (e.g., COVID-19, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection).
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reactions</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">OMVOH</content>
                                          <br/>
                                          <content styleCode="bold">300 mg Intravenous Infusion</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">N=958</content>
                                          <br/>
                                          <content styleCode="bold">n (%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <br/>
                                          <content styleCode="bold">N=321</content>
                                          <br/>
                                          <content styleCode="bold">n (%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper respiratory tract infections<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">72 (8%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">20 (6%)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Arthralgia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">20 (2%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4 (1%)
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In the induction study (UC-1), infusion-related hypersensitivity reactions were reported by 4 (0.4%) subjects treated with OMVOH and 1 (0.3%) subject treated with placebo.
</paragraph>
                              <paragraph>
                                 <linkHtml href="#t3">Table 3</linkHtml> summarizes the adverse reactions reported in at least 2% of subjects and at a higher frequency than placebo during the 40-week controlled period of UC-2.
</paragraph>
                              <table ID="t3" width="100%">
                                 <caption>Table 3: Adverse Reactions<sup>a</sup> in Subjects with Ulcerative Colitis through Week 40 In a Placebo-Controlled Maintenance Study (UC-2)
</caption>
                                 <col width="33.333%" align="left"/>
                                 <col width="33.400%" align="left"/>
                                 <col width="33.267%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> Reported in at least 2% of subjects and at a higher frequency than placebo
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> OMVOH 200 mg as a subcutaneous injection at Week 12 and every 4 weeks thereafter for up to an additional 40 weeks.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> Upper respiratory tract infections includes related terms (e.g., COVID-19, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection).
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> Injection site reactions includes related terms (e.g., erythema, hypersensitivity, pain, reaction, and urticaria at the injection site).
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> Rash is composed of several similar terms.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="3" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>f</sup> Herpes viral infection includes related terms (e.g., herpes zoster, herpes simplex, and oral herpes).
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Adverse Reactions</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">OMVOH</content>
                                          <br/>
                                          <content styleCode="bold">200 mg Subcutaneous Injection</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">N=389</content>
                                          <br/>
                                          <content styleCode="bold">n (%)</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo</content>
                                          <br/>
                                          <br/>
                                          <content styleCode="bold">N=192</content>
                                          <br/>
                                          <content styleCode="bold">n (%)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper respiratory tract infections<sup>c</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">53 (14%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">23 (12%)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Injection site reactions<sup>d</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">34 (9%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8 (4%)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Arthralgia
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">26 (7%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8 (4%)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Rash<sup>e</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">16 (4%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2 (1%)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">16 (4%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2 (1%)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Herpes viral infection<sup>f</sup>
                                       </td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">9 (2%)
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1 (1%)
</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s30">
                                 <id root="7c0abdd9-fb1a-47c2-acd6-c367c6bfd3c6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Infections</content>
                                    </paragraph>
                                    <paragraph>In UC-1 through Week 12, infections were reported by 145 (15%) subjects treated with OMVOH 300 mg and 45 (14%) subjects treated with placebo. Serious infections were reported by less than 1% in both groups. Serious infections in the OMVOH group included intestinal sepsis, listeria sepsis, and pneumonia.
</paragraph>
                                    <paragraph>In the maintenance study (UC-2) through Week 40 (a total of 52 weeks of treatment), infections were reported by 93 (24%) subjects treated with OMVOH 200 mg and 44 (23%) subjects treated with placebo. A case of COVID-19 pneumonia was reported as a serious infection in the OMVOH group.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s31">
                                 <id root="9362c159-10ac-48bf-9253-79cec390177e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Enzyme Elevations</content>
                                    </paragraph>
                                    <paragraph>In UC-1 through Week 12, alanine aminotransferase (ALT) ≥5X ULN was reported by 1 (0.1%) subject treated with OMVOH 300 mg and 1 (0.3%) subject treated with placebo. Aspartate aminotransferase (AST) ≥5X ULN was reported by 2 (0.2%) subjects treated with OMVOH 300 mg and no subject treated with placebo. These elevations have been noted with and without concomitant elevations in total bilirubin.
</paragraph>
                                    <paragraph>In UC-2 through Week 40 (a total of 52 weeks of treatment), 3 (0.8%) subjects treated with OMVOH 200 mg reported ALT ≥5X ULN and 3 (0.8%) subjects reported AST ≥5X ULN; with or without concomitant elevations in total bilirubin. No subjects treated with placebo experienced similar elevations <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.4</linkHtml>)]</content>.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s32">
                           <id root="d04a591a-9f31-450b-ba72-6061f1691b93"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Crohn's Disease</content>
                              </paragraph>
                              <paragraph>OMVOH was studied up to 52 weeks in subjects with moderately to severely active Crohn's disease in a randomized, double-blind, placebo-controlled study (CD-1). The safety population consisted of 630 subjects who received OMVOH 900 mg administered as an intravenous infusion during induction at Weeks 0, 4, and 8 followed by OMVOH 300 mg administered as a subcutaneous injection every 4 weeks and 211 subjects who received placebo <content styleCode="italics">[see Clinical Trials (<linkHtml href="#s76">14.2</linkHtml>)]</content>. Eighty-five of the 211 placebo subjects in the safety population who did not achieve clinical response by patient-reported outcome at Week 12 were switched to blinded induction and maintenance treatment with OMVOH. Observed data from these 85 subjects are included in the placebo cohort up to Week 12 and in the OMVOH cohort after Week 12. In CD-1, OMVOH and placebo-treated subjects had different lengths of exposure, therefore, exposure adjusted incidence rates (EAIRs) are also displayed in <linkHtml href="#t4">Table 4</linkHtml> to compare adverse reactions.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s33">
                                 <id root="f890adcc-71a2-48ce-b59a-f5d8fa5be2bf"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Common Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>
                                       <linkHtml href="#t4">Table 4</linkHtml> summarizes the frequencies and EAIRs per 100 person-years (PY) for adverse reactions reported in at least 5% of subjects treated with OMVOH and at a higher frequency than placebo during CD-1.
</paragraph>
                                    <table ID="t4" width="100%">
                                       <caption>Table 4: Adverse Reactions<sup>a</sup> in Subjects with Crohn's Disease through Week 52 In a Placebo-Controlled Study (CD-1)
</caption>
                                       <col width="30.157%" align="left"/>
                                       <col width="29.424%" align="left"/>
                                       <col width="40.420%" align="left"/>
                                       <tfoot>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">Abbreviations: EAIR, exposure-adjusted incidence rate; PY, person-years
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>a</sup> Reported in at least 5% of subjects and at a higher frequency than placebo
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>b</sup> Following OMVOH 900 mg as an intravenous infusion at Week 0, Week 4, and Week 8, subjects received OMVOH 300 mg as a subcutaneous injection at Week 12 and every 4 weeks thereafter for up to an additional 40 weeks. In addition, eighty-five placebo subjects who did not achieve clinical response by patient-reported outcome at Week 12 were switched to blinded induction and maintenance treatment with OMVOH. The observed data after Week 12 from these eighty-five subjects were included in the OMVOH cohort.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>c</sup> EAIRs are per 100 PY. The EAIR per 100 PY can be interpreted as an estimated number of first occurrences of the adverse reaction of interest if 100 subjects were treated for one year.
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>d</sup> Upper respiratory tract infections includes related terms (e.g., COVID-19, nasopharyngitis, pharyngitis, rhinitis, sinusitis, and upper respiratory tract infection).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>e</sup> Injection site reactions includes related terms (e.g., erythema, hematoma, induration, pain, pruritus, and reaction at the injection site).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>f</sup> Headache includes related terms (i.e., headache and migraine).
</paragraph>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td colspan="3" align="left" valign="top">
                                                <paragraph styleCode="footnote">
                                                   <sup>g</sup> Elevated liver tests include related terms (e.g., ALT increased, AST increased, alkaline phosphatase increased, bilirubin increased, and GGT increased)
</paragraph>
                                             </td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                                <content styleCode="bold">Adverse Reactions</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">OMVOH</content>
                                                <content styleCode="bold">
                                                   <sup>b</sup>
                                                </content>
                                                <br/>
                                                <content styleCode="bold">N=715, PY=655</content>
                                                <br/>
                                                <content styleCode="bold">n (%) [EAIR</content>
                                                <content styleCode="bold">
                                                   <sup>c</sup>
                                                </content>
                                                <content styleCode="bold">]</content>
                                             </td>
                                             <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                                <content styleCode="bold">Placebo</content>
                                                <br/>
                                                <content styleCode="bold">N=211, PY=120</content>
                                                <br/>
                                                <content styleCode="bold">n (%) [EAIR</content>
                                                <content styleCode="bold">
                                                   <sup>c</sup>
                                                </content>
                                                <content styleCode="bold">]</content>
                                             </td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Upper respiratory tract infections<sup>d</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">199 (28) [37]
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">47 (22) [47]
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Injection site reactions<sup>e</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">69 (10) [11]
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8 (4) [7]
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache<sup>f</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">45 (6) [7]
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">9 (4) [8]
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Arthralgia
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">44 (6) [7]
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">11 (5) [10]
</td>
                                          </tr>
                                          <tr>
                                             <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Elevated liver tests<sup>g</sup>
                                             </td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">36 (5) [6]
</td>
                                             <td align="center" valign="top" styleCode="Botrule Rrule">8 (4) [7]
</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20250116"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s34">
                                 <id root="850ae887-80a7-44d1-a35e-a062ae08bf5e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Hepatic Enzyme Elevations</content>
                                    </paragraph>
                                    <paragraph>Of the subjects with reported adverse reactions of elevated liver tests (<content styleCode="italics">see
</content>
                                       <linkHtml href="#t4">Table 4</linkHtml>), 3 subjects treated with OMVOH reported ALT ≥5X ULN and 2 subjects reported AST ≥5X ULN. Neither subject had a concomitant elevation in total bilirubin. No subjects treated with placebo experienced similar elevations.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s35">
                                 <id root="e9246472-076f-4b6d-a0d5-d41a1369dbda"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Less Common Adverse Reactions (&lt;5%)</content>
                                    </paragraph>
                                    <paragraph>In CD-1 through Week 52, urticaria was reported by 13 (2%, 2 per 100 PY) subjects treated with OMVOH and no subjects treated with placebo.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s36">
                                 <id root="ef2a0395-7bbf-44cb-b3e1-a5f1f1ab0075"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Infections</content>
                                    </paragraph>
                                    <paragraph>In CD-1 through Week 52, infections were reported by 282 (39%, 58 per 100 PY) subjects treated with OMVOH and 73 (35%, 81 per 100 PY) subjects treated with placebo. Serious infections in the OMVOH group included abscess (including abdominal abscess, anal abscess, gluteal abscess, and perineal abscess), cellulitis, pneumonia, and sepsis.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s37">
               <id root="eef4c138-c802-41de-9006-908e863f1f0f"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <effectiveTime value="20250115"/>
               <component>
                  <section ID="s38">
                     <id root="aaf11cb5-091a-4a50-a370-96c5089e31a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 CYP450 Substrates
</title>
                     <text>
                        <paragraph>Increased concentrations of cytokines (e.g., IL-1, IL-6, IL-10, TNFα, IFN) during chronic inflammation associated with certain diseases including Crohn's disease may suppress the formation of CYP450 enzymes. Therapeutic proteins, including mirikizumab-mrkz, that decrease the concentrations of these pro-inflammatory cytokines may increase the formation of CYP450 enzymes resulting in decreased CYP450 substrate exposure. Upon initiation or discontinuation of OMVOH in patients treated with concomitant CYP450 substrates, monitor drug concentrations or other therapeutic parameters, and adjust the dosage of the CYP450 substrate as needed. See the prescribing information of specific CYP450 substrates.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s39">
               <id root="ec0668a5-3c7e-46fe-b2e6-abe8342b2e44"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20250115"/>
               <component>
                  <section ID="s40">
                     <id root="ab3e707d-8958-423b-958b-7c708ca39e81"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s41">
                           <id root="f1ffefe4-96e1-4548-a56b-09899e5dc3a2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Exposure Registry</content>
                              </paragraph>
                              <paragraph>There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to OMVOH during pregnancy. Pregnant women exposed to OMVOH and healthcare providers are encouraged to call Eli Lilly and Company at 1-800-Lilly-Rx (1-800-545-5979).
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s42">
                           <id root="f5f7de94-094d-41c6-9d11-a9571ca584da"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from case reports of mirikizumab-mrkz use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Although there are no data on mirikizumab-mrkz, monoclonal antibodies can be actively transported across the placenta, and mirikizumab-mrkz may cause immunosuppression in the in utero-exposed infant. An enhanced pre- and post-natal development study conducted in pregnant monkeys at a dose 20 times the maximum recommended human dose (MRHD) revealed no adverse developmental effects to the developing fetus, or harm to infant monkeys from birth through 6 months of age. There are risks of adverse pregnancy outcomes associated with increased disease activity in women with inflammatory bowel disease <content styleCode="italics">(see Clinical Considerations)</content>.
</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s43">
                           <id root="b37456f0-850a-4bcd-a89f-eb68c44728d4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s44">
                                 <id root="3b9222ce-4930-46b0-aac4-6128e9655756"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and Embryo/Fetal Risk</content>
                                    </paragraph>
                                    <paragraph>Published data suggest that the risk of adverse pregnancy outcomes in women with inflammatory bowel disease (IBD) is associated with increased disease activity. Adverse pregnancy outcomes include preterm delivery (before 37 weeks gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s45">
                                 <id root="c95e23ca-e0ba-4f59-9319-cda4c7fad05e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester. It is unclear whether mirikizumab-mrkz may interfere with an infant's immune response to infections. Therefore, monitoring for the development of serious infection during the first 2 months of life in infants exposed in utero is recommended.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s46">
                           <id root="6a0b943d-7361-49ac-85da-1de579978553"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s47">
                                 <id root="341b4a3c-6487-4fff-b28d-2e6880aa3e09"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>An enhanced pre- and postnatal development study was conducted in cynomolgus monkeys administered mirikizumab-mrkz by intravenous injection during organogenesis to parturition at a dose of 300 mg/kg twice weekly (20 times the MRHD based on exposure comparisons). Mirikizumab-mrkz crossed the placenta in monkeys. No maternal toxicity was noted in this study. No mirikizumab-mrkz-related effects on morphological, functional or immunological development were observed in infant monkeys from birth through 6 months of age. However, incidences of embryo/fetal loss were higher in the treated groups compared to control (6.7% [1 of 15] in controls vs 26.7% [4 of 15] at 300 mg/kg (20 times the MRHD, based on exposure comparisons) but were within the range of historical control data. Following delivery, most adult female cynomolgus monkeys and all infants from the mirikizumab-mrkz-treated group had measurable serum concentrations up to 28 days postpartum. In the infant monkeys, mean serum concentrations were approximately 4.8 times the respective mean maternal concentrations.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s48">
                     <id root="2fe5502e-9992-4a4e-8ee6-e9051eb706e3"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s49">
                           <id root="709cb92d-36dd-4566-a8c8-a9f0af3d5069"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of mirikizumab-mrkz in human milk, the effects on the breastfed infant, or the effects on milk production. Endogenous maternal IgG and monoclonal antibodies are transferred in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to mirikizumab-mrkz are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for OMVOH and any potential adverse effects on the breastfed infant from OMVOH or from the underlying maternal condition.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s50">
                     <id root="09e19965-65fb-45f6-81a4-ea3cf88b76ab"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of OMVOH have not been established in pediatric patients.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s51">
                     <id root="915cf3b2-adcd-40bf-8718-567543fa05b7"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>Of the 795 OMVOH-treated subjects in the two ulcerative colitis clinical studies, 64 subjects (8%) were 65 years of age and older, while 10 subjects (1%) were 75 years of age and older. Of the 715 OMVOH-treated subjects in the Crohn's disease clinical study, 22 subjects (3%) were 65 years of age and older, while 6 subjects (1%) were 75 years of age and older). These clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger adult subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. No clinically meaningful differences in the pharmacokinetics of mirikizumab-mrkz were observed in subjects 65 years of age and older compared to younger adult subjects <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s59">12.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s52">
               <id root="44893158-c31a-49ca-8b75-cb3573d81762"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Mirikizumab-mrkz is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody that is directed against the p19 subunit of IL-23 and does not bind IL-12. Mirikizumab-mrkz is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology and it is composed of two identical light chain polypeptides and two identical heavy chain polypeptides with an overall molecular weight of approximately 147 kDa.
</paragraph>
               </text>
               <effectiveTime value="20250115"/>
               <component>
                  <section ID="s53">
                     <id root="4e90124d-c388-45d0-aa1c-763c3244048e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">OMVOH for intravenous infusion for ulcerative colitis and Crohn's disease</content>
                        </paragraph>
                        <paragraph>OMVOH (mirikizumab-mrkz) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution in a single-dose vial for intravenous infusion after dilution. Each mL contains 20 mg of mirikizumab-mrkz, anhydrous citric acid (0.4 mg), polysorbate 80 (0.5 mg), sodium chloride (8.8 mg), sodium citrate (2.1 mg), and Water for Injection. The OMVOH solution has a pH range of 5.0 to 6.0.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s54">
                     <id root="22b4796e-650c-45ff-9392-15fee6d848c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">OMVOH (mirikizumab-mrkz) injection 100 mg/mL prefilled pen or prefilled syringe for subcutaneous use for ulcerative colitis and Crohn's disease</content>
                        </paragraph>
                        <paragraph>OMVOH (mirikizumab-mrkz) injection is a sterile, preservative free, clear to opalescent, colorless to slightly yellow to slightly brown solution for subcutaneous use available as 100 mg of mirikizumab-mrkz in a 1 mL single-dose prefilled pen or single-dose prefilled syringe. The prefilled pen and prefilled syringe contain a 1 mL glass syringe with a fixed 27-gauge ½ inch needle. The OMVOH 100 mg prefilled pen and prefilled syringe are manufactured to deliver 100 mg of mirikizumab-mrkz.
</paragraph>
                        <paragraph>Each mL is composed of 100 mg mirikizumab-mrkz, histidine (0.1 mg), L-histidine hydrochloride monohydrate (0.9 mg), mannitol (33 mg), polysorbate 80 (0.3 mg), sodium chloride (2.9 mg), and Water for Injection. The OMVOH solution has a pH range of 5.0 to 5.8.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s55">
                     <id root="76416f29-2483-4938-b739-b2c22ae015f2"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">OMVOH (mirikizumab-mrkz) injection 200 mg/2 mL prefilled pen or 200 mg/2 mL (100 mg/mL) prefilled syringe for subcutaneous use for Crohn's disease</content>
                        </paragraph>
                        <paragraph>OMVOH (mirikizumab-mrkz) injection is a sterile, preservative free, clear to opalescent, colorless to slightly yellow to slightly brown solution for subcutaneous use. The 2 mL prefilled pen and prefilled syringe each contain a 2 mL glass syringe with a fixed 27-gauge 8 mm needle. The OMVOH 200 mg prefilled pen and prefilled syringe are manufactured to deliver 200 mg of mirikizumab-mrkz.
</paragraph>
                        <paragraph>Each mL is composed of 100 mg mirikizumab-mrkz, histidine (0.1 mg), L-histidine hydrochloride monohydrate (0.9 mg), mannitol (33 mg), polysorbate 80 (0.3 mg), sodium chloride (2.9 mg), and Water for Injection. The OMVOH solution has a pH range of 5.0 to 5.8.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s56">
               <id root="4caeebb2-0f42-44c0-8bf0-764939a56ee4"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20250115"/>
               <component>
                  <section ID="s57">
                     <id root="3bc8b984-5d1d-44a8-b485-b7cf5817fd15"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.
</paragraph>
                        <paragraph>IL-23 is involved in mucosal inflammation and affects the differentiation, expansion, and survival of T cell subsets, and innate immune cell subsets, which represent sources of pro-inflammatory cytokines. Research in animal models has shown that pharmacologic inhibition of IL-23p19 can ameliorate intestinal inflammation.
</paragraph>
                        <paragraph>Mirikizumab-mrkz inhibits the release of pro-inflammatory cytokines and chemokines.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="9d5425fc-47b7-485c-ba4f-61023bc1baef"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <text>
                        <paragraph>In both study UC-1 (induction) and study UC-2 (maintenance), a positive relationship was observed between mirikizumab-mrkz average concentration and rates of clinical remission and clinical response <content styleCode="italics">[see Clinical Studies (<linkHtml href="#s70">14.1</linkHtml>)]</content>.
</paragraph>
                        <paragraph>Mirikizumab exposure response relationships have not been fully characterized in subjects with Crohn's disease.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
               <component>
                  <section ID="s59">
                     <id root="dfbf0c4d-f4e5-42d9-999e-95be08f365cb"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics
</title>
                     <text>
                        <paragraph>Mirikizumab-mrkz exhibited linear pharmacokinetics with dose-proportional increase in exposure over a dose range of 60 to 2400 mg given as an intravenous injection or over a dose range of 200 to 400 mg given as a subcutaneous injection, in healthy volunteers. There was no apparent accumulation of mirikizumab-mrkz concentrations in serum over time when administered as a subcutaneous injection every 4 weeks to subjects with ulcerative colitis or Crohn's disease. The estimated exposure parameters of mirikizumab-mrkz at steady state are summarized in <linkHtml href="#t5">Tables 5</linkHtml> for ulcerative colitis and <linkHtml href="#t6">6</linkHtml> for Crohn's disease.
</paragraph>
                        <table ID="t5" width="100%">
                           <caption>Table 5: Mirikizumab-mrkz Estimated Systemic Exposure at Steady State in Subjects with Ulcerative Colitis
</caption>
                           <col width="33.333%" align="left"/>
                           <col width="33.333%" align="left"/>
                           <col width="33.333%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> OMVOH 300 mg as an intravenous infusion over at least 30 minutes at Weeks 0, 4, and 8.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> OMVOH 200 mg as 2 subcutaneous injections (100 mg/mL each) at Week 12 and every 4 weeks thereafter for up to an additional 40 weeks.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>c</sup> AUC<sub>tau, ss</sub> = area under the concentration-versus-time curve over one dosing interval at steady state; C<sub>max, ss</sub> = maximum concentration at steady state; C<sub>trough, ss</sub> = concentration at the end of the dosing interval at steady state; CV = geometric coefficient of variation.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">OMVOH</content>
                                    <br/>
                                    <content styleCode="bold">300 mg Intravenous Infusion</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                    <br/>Geometric mean (CV%)
</td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">OMVOH</content>
                                    <br/>
                                    <content styleCode="bold">200 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                    <br/>Geometric mean (CV%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">C<sub>max, ss</sub> (μg/mL)<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">99.7 (22.7%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10.1 (52.1%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">AUC<sub>tau, ss</sub> (μg*day/mL)<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">538 (34.4%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">160 (57.6%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">C<sub>trough, ss</sub> (μg/mL)<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">2.75 (101%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1.70 (83.3%)
</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="t6" width="100%">
                           <caption>Table 6: Mirikizumab-mrkz Estimated Systemic Exposure at Steady State in Subjects with Crohn's Disease
</caption>
                           <col width="33.333%" align="left"/>
                           <col width="33.333%" align="left"/>
                           <col width="33.333%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> OMVOH 900 mg as an intravenous infusion over at least 90 minutes at Weeks 0, 4, and 8.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> OMVOH 300 mg as 2 subcutaneous injections (100 mg/mL and 200 mg/2 mL) at Week 12 and every 4 weeks thereafter up to Week 52.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>c</sup> AUC<sub>tau, ss</sub> = area under the concentration-versus-time curve over one dosing interval at steady state; C<sub>max, ss</sub> = maximum concentration at steady state; C<sub>trough, ss</sub> = concentration at the end of the dosing interval at steady state; CV = geometric coefficient of variation.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">OMVOH</content>
                                    <br/>
                                    <content styleCode="bold">900 mg Intravenous Infusion</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                    <br/>Geometric mean (CV%)
</td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">OMVOH</content>
                                    <br/>
                                    <content styleCode="bold">300 mg Subcutaneous Injection</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                    <br/>Geometric mean (CV%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">C<sub>max, ss</sub> (μg/mL)<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">332 (21%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">13.6 (48%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">AUC<sub>tau, ss</sub> (μg*day/mL)<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">1820 (38%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">220 (56%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">C<sub>trough, ss</sub> (μg/mL)<sup>c</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10.4 (108%)
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">2.52 (88%)
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s60">
                           <id root="78031fc3-7ef5-4546-994b-cc753edea19e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following subcutaneous dosing of OMVOH for ulcerative colitis median (range) T<sub>max</sub> was 5 (3.08 to 6.75) days post dose and geometric mean (CV%) absolute bioavailability was 44% (34%).
</paragraph>
                              <paragraph>Following subcutaneous dosing of OMVOH for Crohn's disease, median (range) T<sub>max</sub> was 5 (3 to 6.83) days post dose and geometric mean (CV%) absolute bioavailability was 36.3% (31%).
</paragraph>
                              <paragraph>Injection site location (abdomen, upper arm, or thigh) did not significantly influence bioavailability of mirikizumab-mrkz following subcutaneous injection.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s61">
                           <id root="fae64f0e-ce02-4cff-838b-1fa7fb1fca12"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>In subjects with ulcerative colitis, the geometric mean (CV%) total volume of distribution was 4.83 L (21%).
</paragraph>
                              <paragraph>In subjects with Crohn's disease, the geometric mean (CV%) total volume of distribution was 4.4 L (14%).
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s62">
                           <id root="6b07060c-e0fd-4db4-8d1c-0f7da8eaf963"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism/Elimination</content>
                              </paragraph>
                              <paragraph>Mirikizumab-mrkz is a humanized IgG4 monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.
</paragraph>
                              <paragraph>In subjects with ulcerative colitis, the geometric mean (CV%) clearance was 0.0229 L/hours (34%) and the geometric mean (CV%) elimination half-life was 9.3 days (40%). Clearance is independent of dose.
</paragraph>
                              <paragraph>In subjects with Crohn's disease, the geometric mean (CV%) clearance was 0.0202 L/hours (38%) and the geometric mean (CV%) elimination half-life was 9.3 days (26%). Clearance is independent of dose.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s63">
                           <id root="4dd2c9c3-cccd-4c45-b71b-d050894872eb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>There were no clinically significant differences in the pharmacokinetics of mirikizumab-mrkz based on age (18 to 79 years), sex, race (White or Asian), or mild and moderate renal impairment (i.e., estimated creatinine clearance by Cockcroft-Gault equation: 30 to 89 mL/min).
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s64">
                                 <id root="ad3d3a63-24af-44ec-9a87-149379550c39"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Body Weight</content>
                                    </paragraph>
                                    <paragraph>Following intravenous administration of 300 mg, the recommended induction dose, in subjects with ulcerative colitis weighing 90 kg or greater, the estimated geometric mean mirikizumab-mrkz average concentration (C<sub>avg</sub>) was 20% lower compared with subjects weighing less than 90 kg. Following subcutaneous administration of 200 mg, the recommended maintenance dose, in subjects with ulcerative colitis weighing 90 kg or greater, the estimated geometric mean C<sub>avg</sub> was 38% lower compared with subjects weighing less than 90 kg. In Study UC-2 (maintenance), the rate of clinical remission and clinical response did not differ significantly between subjects weighing 90 kg or greater and subjects weighing less than 90 kg.
</paragraph>
                                    <paragraph>Following intravenous administration of 900 mg, the recommended induction dose, in subjects with Crohn's disease weighing 90 kg or greater, the estimated geometric mean mirikizumab-mrkz C<sub>avg</sub> was 13% lower compared with subjects weighing less than 90 kg. Following subcutaneous administration of 300 mg, the recommended maintenance dose, in subjects with Crohn's disease weighing 90 kg or greater, the estimated geometric mean C<sub>avg</sub> was 34% lower compared with subjects weighing less than 90 kg. The rate of clinical remission and clinical response in Crohn's disease did not differ significantly between subjects weighing 90 kg or greater and subjects weighing less than 90 kg.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s65">
                           <id root="475d889b-fe18-4088-8e0d-1ffb5306613c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>Population pharmacokinetic analyses indicated that the clearance of OMVOH was not impacted by concomitant administration of aminosalicylates, corticosteroids, or oral immunomodulators (6-MP, AZA, MTX, tioguanine) in subjects with ulcerative colitis or Crohn's disease.
</paragraph>
                              <paragraph>No drug-drug interaction studies were conducted in subjects with ulcerative colitis or Crohn's disease at the recommended dosage. Based on a clinical drug-drug interaction study conducted in subjects with another condition, multiple subcutaneous doses of 250 mg every 4 weeks of mirikizumab-mrkz did not result in changes in the exposure of midazolam (CYP3A substrate), warfarin (CYP2C9 substrate), dextromethorphan (CYP2D6 substrate), omeprazole (CYP2C19 substrate), or caffeine (CYP1A2 substrate).
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s66">
                     <id root="7f2f7e49-78b3-4d0c-b7a0-ff2dce54b020"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity
</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of mirikizumab-mrkz or of other mirikizumab products.
</paragraph>
                        <paragraph>During the 52-week treatment period in studies UC-1 and UC-2, 23% (88/378) of OMVOH-treated subjects at the recommended dosage and evaluable for assessment, developed anti-mirikizumab-mrkz antibodies (referred to as anti-drug antibodies (ADA)). Of those who developed ADA, 33/88 (38%) developed titers ≥1:160. Of these 33 OMVOH-treated subjects, 10 had reduced serum trough concentrations of mirikizumab-mrkz compared to subjects who did not develop anti-mirikizumab-mrkz antibodies, and 5 of these 10 subjects did not achieve clinical response at Week 52. There is insufficient data to assess whether the observed ADA-associated pharmacokinetic changes reduced effectiveness. There is no identified clinically significant effect of ADA on the safety of OMVOH over the treatment duration of 52-weeks.
</paragraph>
                        <paragraph>During the 52-week treatment period in study CD-1, 13% (79/622) of OMVOH-treated subjects at the recommended dosage and evaluable for assessment developed ADA. There is no identified clinically significant effect of ADA on the pharmacokinetics, effectiveness, or safety of OMVOH over the treatment duration of 52-weeks.
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s67">
               <id root="fbb6fc3c-f503-45ce-bd04-7a9293a4898d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20250115"/>
               <component>
                  <section ID="s68">
                     <id root="4055fd5c-9df9-40de-ab42-ceff659b734a"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <text>
                        <paragraph>Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of mirikizumab-mrkz.
</paragraph>
                        <paragraph>No organ weight or histopathology effects were observed in the male or female reproductive tract in sexually mature cynomolgus monkeys that received subcutaneous mirikizumab-mrkz once weekly for 26 weeks, at a dose of 100 mg/kg (at least 2 times the MRHD of mirikizumab-mrkz, based on exposure comparisons).
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s69">
               <id root="840b4d0e-eef3-4df9-99f9-bfe275f9aa82"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <effectiveTime value="20250115"/>
               <component>
                  <section ID="s70">
                     <id root="e220b449-285a-4093-a5aa-b46744664995"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Ulcerative Colitis
</title>
                     <text>
                        <paragraph>The safety and efficacy of OMVOH was evaluated in two randomized, double-blind, placebo-controlled clinical studies, one induction study [UC-1 (NCT03518086)] and one maintenance study [UC-2 (NCT03524092)], in adult subjects with moderately to severely active ulcerative colitis who had inadequate response, loss of response, or failed to tolerate any of the following: corticosteroids, 6-mercaptopurine, azathioprine, biologic therapy (TNF blocker, vedolizumab), or tofacitinib. The 12-week intravenous induction study (UC-1) was followed by the 40-week subcutaneous randomized withdrawal maintenance study (UC-2).
</paragraph>
                     </text>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s71">
                           <id root="d7e562ff-a05c-4b8d-a1ba-a7b826b1afc2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study UC-1</content>
                              </paragraph>
                              <paragraph>In UC-1, efficacy was evaluated in 1062 subjects who were randomized 3:1 at Week 0 to receive 300 mg OMVOH or placebo by intravenous infusion at Week 0, Week 4, and Week 8. Subjects had a mean age of 43 years (range 18 to 79 years); 40% were female; and 71% identified as White, 25% as Asian, 1% as American Indian or Alaska Native, 1% as Black or African American, and &lt;2% as another racial group or did not report their racial group. Subjects were permitted to use stable doses of aminosalicylates, immunomodulators (6-mercaptopurine, azathioprine, methotrexate), and oral corticosteroids (prednisone ≤20 mg/day or equivalent, extended-release budesonide 9 mg/day, beclomethasone dipropionate 5 mg/day). At baseline, 41% of subjects were receiving oral corticosteroids, 24% were receiving immunomodulators, and 75% were receiving aminosalicylates.
</paragraph>
                              <paragraph>At baseline, 57% were biologic and Janus Kinase inhibitor (JAKi) naive, 41% had failed at least one biologic, 3% had failed a JAKi, and 2% had previously received but had not failed a biologic or JAKi.
</paragraph>
                              <paragraph>Disease activity was assessed based on the modified Mayo score (mMS), which ranges from 0 to 9 and has three subscores that are each scored from 0 (normal) to 3 (most severe): stool frequency, rectal bleeding, and findings on centrally read endoscopy subscore. At baseline, subjects had a mMS of 5 to 9, including a centrally read endoscopy subscore of 2 or 3. An endoscopy subscore of 2 was defined by marked erythema, absent vascular pattern, friability, and erosions; and a subscore of 3 was defined by spontaneous bleeding and ulceration. Subjects had a median mMS of 7, and 58% had severely active disease (mMS of 7 to 9).
</paragraph>
                              <paragraph>The primary endpoint was clinical remission at Week 12. The secondary endpoints were clinical response, endoscopic improvement, and histologic-endoscopic mucosal improvement (<content styleCode="italics">see
</content>
                                 <linkHtml href="#t7">Table 7</linkHtml>).
</paragraph>
                              <table ID="t7" width="100%">
                                 <caption>Table 7: Proportion of Subjects with Ulcerative Colitis Meeting Efficacy Endpoints in UC-1 at Week 12
</caption>
                                 <col width="27.250%" align="left"/>
                                 <col width="23.700%" align="left"/>
                                 <col width="23.700%" align="left"/>
                                 <col width="25.350%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">JAKi = Janus Kinase inhibitor
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> OMVOH 300 mg as an intravenous infusion at Week 0, Week 4, and Week 8.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> Adjusted treatment difference based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> Clinical remission based on mMS is defined as: stool frequency subscore = 0 or 1, rectal bleeding subscore = 0, and centrally read endoscopy subscore = 0 or 1 (excluding friability).
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> Tested at an alpha level of 0.00125, with a p-value &lt;0.001.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> Prior biologic or JAKi failure includes loss of response, inadequate response, or intolerance to one or more biologic therapy (TNF blocker or vedolizumab), or tofacitinib.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>f</sup> Clinical response is defined as a decrease in the mMS of ≥2 points with ≥30% decrease from baseline, and either a decrease of ≥1 point in the rectal bleeding subscore from baseline or a rectal bleeding subscore of 0 or 1.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>g</sup> Endoscopic improvement is defined as a centrally read endoscopy subscore of 0 or 1 (excluding friability).
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>h</sup> Histologic-endoscopic mucosal improvement is defined as achieving both endoscopic improvement (centrally read endoscopy subscore of 0 or 1, excluding friability) and histologic improvement (neutrophil infiltration in &lt;5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue based on the Geboes scoring system).
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Endpoint</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo</content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">OMVOH 300 mg Intravenous Infusion</content>
                                          <content styleCode="bold">
                                             <sup>a</sup>
                                          </content>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Treatment Difference</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(95% CI)</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Clinical remission<sup>c</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 267<br/>15%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 795<br/>24%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">10%<sup>d</sup>
                                          <br/>(5, 15)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 155<br/>18%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 450<br/>31%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>e</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 107<br/>8%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 331<br/>15%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Clinical response<sup>f</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 267<br/>43%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 795<br/>65%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">22%<sup>d</sup>
                                          <br/>(15, 28)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 155<br/>52%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 450<br/>71%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>d, e</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 107<br/>31%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 331<br/>56%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Endoscopic improvement<sup>g</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 267<br/>21%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 795<br/>34%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">14%<sup>d</sup>
                                          <br/>(8, 20)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 155<br/>28%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 450<br/>44%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>e</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 107<br/>10%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 331<br/>22%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Histologic-endoscopic mucosal improvement<sup>h</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 267<br/>14%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 795<br/>25%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">11%<sup>d</sup>
                                          <br/>(6, 16)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 155<br/>19%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 450<br/>34%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>e</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 107<br/>7%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 331<br/>13%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Study UC-1 was not designed to evaluate the relationship of histologic-endoscopic mucosal improvement at Week 12 to disease progression and long-term outcomes.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s72">
                                 <id root="54197bd1-13b4-4645-8b73-20f3c1e0c9b9"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Rectal Bleeding and Stool Frequency Subscores</content>
                                    </paragraph>
                                    <paragraph>Decreases in rectal bleeding and stool frequency subscores were observed as early as Week 3 in subjects treated with OMVOH compared to subjects on placebo.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="s73">
                           <id root="67c15f60-50b8-4f60-b081-8388cfb5cb61"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Study UC-2</content>
                              </paragraph>
                              <paragraph>The maintenance study (UC-2) evaluated 506 subjects who achieved clinical response at Week 12 in Study UC-1. These subjects were randomized 2:1 to receive 200 mg OMVOH or placebo subcutaneously every 4 weeks for 40 weeks in UC-2, for a total of 52 weeks of treatment. Subjects who were on concomitant ulcerative colitis therapies during UC-1 were required to continue on stable doses of oral aminosalicylates and immunomodulators (6-mercaptopurine, azathioprine, methotrexate). Corticosteroid tapering was required for subjects who were receiving corticosteroids at baseline and achieved clinical response in UC-1.
</paragraph>
                              <paragraph>The primary endpoint was clinical remission at Week 40. The secondary endpoints were endoscopic improvement, maintenance of clinical remission in subjects who achieved clinical remission at Week 12, corticosteroid-free clinical remission, and histologic-endoscopic mucosal improvement (<content styleCode="italics">see
</content>
                                 <linkHtml href="#t8">Table 8</linkHtml>).
</paragraph>
                              <table ID="t8" width="100%">
                                 <caption>Table 8: Proportion of Subjects with Ulcerative Colitis Meeting Efficacy Endpoints in UC-2 at Week 40 (a total of 52 weeks of treatment)
</caption>
                                 <col width="27.475%" align="left"/>
                                 <col width="24.175%" align="left"/>
                                 <col width="24.175%" align="left"/>
                                 <col width="24.175%" align="left"/>
                                 <thead>
                                    <tr>
                                       <th align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Endpoint</content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Placebo</content>
                                          <content styleCode="bold">
                                             <sup>a</sup>
                                          </content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">OMVOH</content>
                                          <br/>
                                          <content styleCode="bold">200 mg</content>
                                          <br/>
                                          <content styleCode="bold">Subcutaneous Injection</content>
                                          <content styleCode="bold">
                                             <sup>b</sup>
                                          </content>
                                       </th>
                                       <th align="center" valign="middle" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Treatment Difference</content>
                                          <content styleCode="bold">
                                             <sup>c</sup>
                                          </content>
                                          <br/>
                                          <content styleCode="bold">(95% CI)</content>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">JAKi = Janus Kinase inhibitor
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup> The placebo arm includes subjects treated with OMVOH during the induction study (UC-1) and were randomized to receive placebo through Week 40.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>b</sup> OMVOH 200 mg as a subcutaneous injection at Week 12 and every 4 weeks thereafter for up to an additional 40 weeks.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>c</sup> Adjusted treatment difference (95% CI) based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>d</sup> Among subjects who achieved clinical response at Week 12 in UC-1 with OMVOH induction treatment.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>e</sup> Clinical remission based on mMS is defined as: stool frequency subscore = 0 or 1, rectal bleeding subscore = 0, and centrally read endoscopy subscore = 0 or 1 (excluding friability).
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>f</sup> p&lt;0.001.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>g</sup> Prior biologic or JAKi failure includes loss of response, inadequate response, or intolerance to one or more biologic therapy (TNF blocker or vedolizumab), or tofacitinib.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>h</sup> Endoscopic improvement is defined as a centrally read endoscopy subscore of 0 or 1 (excluding friability).
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>i</sup> Among subjects who achieved clinical remission at Week 12 in UC-1 with OMVOH induction treatment.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>j</sup> p&lt;0.01.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>k</sup> Corticosteroid-free clinical remission is defined as clinical remission at Week 40 and no corticosteroid use for ≥12 weeks prior to Week 40 assessment.
</paragraph>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>l</sup> Histologic-endoscopic mucosal improvement is defined as achieving both endoscopic improvement (centrally read endoscopy subscore of 0 or 1, excluding friability) and histologic improvement (no neutrophils in crypts or lamina propria, no crypt destruction, and no erosions, ulcerations, or granulation tissue based on the Geboes scoring system).
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Clinical remission<sup>d, e</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 169<br/>27%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 337<br/>51%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">22%<sup>f</sup>
                                          <br/>(14, 31)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 109<br/>33%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 208<br/>53%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>g</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 59<br/>15%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 121<br/>45%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Endoscopic improvement<sup>d, h</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 169<br/>30%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 337<br/>58%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">27%<sup>f</sup>
                                          <br/>(19, 36)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 109<br/>35%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 208<br/>62%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>g</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 59<br/>20%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 121<br/>50%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Maintenance of clinical remission in patients who achieved clinical remission at Week 12<sup>i</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 62<br/>40%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 128<br/>66%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">23%<sup>j</sup>
                                          <br/>(8, 38)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 48<br/>48%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 91<br/>66%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>g</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 14<br/>14%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 34<br/>65%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Corticosteroid-free clinical remission<sup>d, k</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 169<br/>27%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 337<br/>50%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">22%<sup>f</sup>
                                          <br/>(13, 30)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 109<br/>33%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 208<br/>52%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>g</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 59<br/>15%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 121<br/>45%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td colspan="4" align="left" valign="middle" styleCode="Botrule Lrule Rrule">Histologic-endoscopic mucosal improvement<sup>d, l</sup>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total Population
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 169<br/>22%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 337<br/>43%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">19%<sup>f</sup>
                                          <br/>(11, 27)
</td>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Biologic and JAKi naive
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 109<br/>27%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 208<br/>47%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                    <tr>
                                       <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic or JAKi failure<sup>g</sup>
                                       </td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 59<br/>14%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule">N = 121<br/>36%
</td>
                                       <td align="center" valign="middle" styleCode="Botrule Rrule"/>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Study UC-2 was not designed to evaluate the relationship of histologic-endoscopic mucosal improvement at Week 40 to disease progression and long-term outcomes.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                           <component>
                              <section ID="s74">
                                 <id root="97bc52bc-adbd-4d6d-8094-746c2c8ebb76"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Bowel Urgency</content>
                                    </paragraph>
                                    <paragraph>Bowel urgency was assessed during UC-1 and UC-2 with an Urgency Numeric Rating Scale (NRS) of 0 to 10. A greater proportion of subjects with a baseline Urgency NRS weekly average score ≥3 treated with OMVOH compared to placebo reported an Urgency NRS weekly average score of 0 or 1 (39% versus 23%) at Week 40. Urgency NRS weekly average scores of 0 to 1 were also observed in a greater proportion of subjects treated with OMVOH compared to placebo at Week 12.
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                           <component>
                              <section ID="s75">
                                 <id root="ab81a70d-ba3c-460d-91b7-d82b9e7b597b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Endoscopic Assessment</content>
                                    </paragraph>
                                    <paragraph>Normalization of the endoscopic appearance of the mucosa (endoscopic remission) was defined as a Mayo endoscopic subscore of 0. At Week 40 in UC-2, endoscopic remission was observed in a greater proportion of subjects treated with OMVOH compared to placebo (22% versus 14%).
</paragraph>
                                 </text>
                                 <effectiveTime value="20250115"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s76">
                     <id root="b495f7cd-9b37-4d84-8929-1d73ab927c2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Crohn's Disease
</title>
                     <text>
                        <paragraph>The safety and efficacy of OMVOH was evaluated in a randomized, double-blind, placebo-controlled study [CD-1 (NCT03926130)] in adult subjects with moderately to severely active Crohn's disease who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, and methotrexate), and/or biologics (TNF blockers, integrin receptor antagonists).
</paragraph>
                        <paragraph>In CD-1, the efficacy population consisted of 679 subjects who were randomized 3:1 at Week 0 to receive OMVOH 900 mg by intravenous infusion at Week 0, Week 4, and Week 8 followed by a dosage of 300 mg by subcutaneous injection at Week 12 and then every 4 weeks for 40 weeks, or placebo. Subjects had a mean age of 36 years (range 18 to 74 years); 42% were female; and 71% identified as White, 25% as Asian, &lt;1% as American Indian or Alaska Native, 1% as Black or African American, and 2% as another racial group or did not report their racial group. Subjects were permitted to use stable doses of oral corticosteroids (prednisone ≤30 mg/day or equivalent, extended-release budesonide 9 mg/day), immunomodulators (6-mercatopurine, azathioprine, or methotrexate) and/or aminosalicylates. At baseline, 31% of subjects were receiving oral corticosteroids, 26% were receiving immunomodulators, and 44% were receiving aminosalicylates.
</paragraph>
                        <paragraph>At baseline, 47% had a loss of response, inadequate response, or intolerance to one or more biologic therapy.
</paragraph>
                        <paragraph>Disease activity at baseline was assessed by the Crohn's Disease Activity Index (CDAI) and the Simple Endoscopic Score for Crohn's disease (SES-CD). Moderately to severely active CD was defined by a CDAI of ≥220 and an SES-CD ≥7 (centrally read) for subjects with ileal-colonic disease or ≥4 for subjects with isolated ileal disease. At baseline, subjects had a median CDAI of 329 and SES-CD of 12.
</paragraph>
                        <paragraph>The coprimary endpoints of clinical remission by CDAI and endoscopic response by SES-CD were assessed at Week 52. Secondary efficacy endpoints included endoscopic response at Week 12 and endoscopic remission and corticosteroid-free clinical remission at Week 52 (<content styleCode="italics">see
</content>
                           <linkHtml href="#t9">Table 9</linkHtml>).
</paragraph>
                        <table ID="t9" width="100%">
                           <caption>Table 9: Proportion of Subjects with Crohn's Disease Meeting Efficacy Endpoints in CD-1
</caption>
                           <col width="36.920%" align="left"/>
                           <col width="19.880%" align="left"/>
                           <col width="20.820%" align="left"/>
                           <col width="10%" align="left"/>
                           <col width="22.240%" align="left"/>
                           <tfoot>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">CI = confidence interval
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>a</sup> The placebo group includes all 168 subjects randomized to placebo at baseline. Of those, 67 (40%) subjects who did not achieve clinical response by patient-reported outcome at Week 12 were switched to treatment with OMVOH and their efficacy data are included here with the remaining subjects randomized to placebo who did not receive OMVOH.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>b</sup> Following OMVOH 900 mg as an intravenous infusion at Week 0, Week 4, and Week 8, subjects received OMVOH 300 mg as a subcutaneous injection at Week 12 and every 4 weeks thereafter for up to an additional 40 weeks.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>c</sup> Adjusted treatment difference was based on Cochran-Mantel-Haenszel method adjusted for randomization stratification factors.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>d</sup> Clinical remission is defined as CDAI &lt;150.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>e</sup> p-value &lt;0.001.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>f</sup> Prior biologic failure includes loss of response, inadequate response, or intolerance to one or more biologic therapy (TNF blockers, and integrin receptor antagonists).
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>g</sup> Endoscopic response is defined as &gt;50% reduction from baseline in SES-CD total score, based on central reading.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>h</sup> Endoscopic remission is defined as SES-CD total score ≤4 and at least a 2-point reduction from baseline, with no segment subscore &gt;1, based on central reading.
</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top">
                                    <paragraph styleCode="footnote">
                                       <sup>i</sup> Corticosteroid-free clinical remission is defined as subjects who were corticosteroid-free from Week 40 to Week 52, and had a CDAI &lt;150 at Week 52.
</paragraph>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Placebo<sup>a</sup>
                                    </content>
                                 </td>
                                 <td colspan="2" align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">OMVOH</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Treatment Difference</content>
                                    <content styleCode="bold">
                                       <sup>c</sup>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">(95% CI)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Coprimary Endpoints</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">Clinical remission<sup>d</sup> at Week 52
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total population
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 168<br/>36%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 511<br/>53%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">17%<sup>e</sup>
                                    <br/>(9%, 25%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Without prior biologic failure
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 89<br/>45%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 268<br/>56%
</td>
                                 <td rowspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 79<br/>25%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 243<br/>49%
</td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">Endoscopic response<sup>g</sup> at Week 52
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total population
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 168<br/>23%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 511<br/>46%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">23%<sup>e</sup>
                                    <br/>(15%, 30%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Without prior biologic failure
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 89<br/>27%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 268<br/>49%
</td>
                                 <td rowspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 79<br/>18%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 243<br/>43%
</td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Additional Endpoints</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="bottom" styleCode="Botrule Lrule Rrule">Endoscopic response<sup>g</sup> at Week 12
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total population
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 168<br/>11%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 511<br/>32%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">22%<sup>e</sup>
                                    <br/>(16%, 28%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Without prior biologic failure
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 89<br/>12%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 268<br/>37%
</td>
                                 <td rowspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 79<br/>9%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">N = 243<br/>28%
</td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">Corticosteroid-free clinical remission<sup>i</sup> at Week 52
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total population
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 168<br/>35%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 511<br/>50%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">16% <sup>e</sup>
                                    <br/>(7%, 24%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Without prior biologic failure
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 89<br/>43%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 268<br/>54%
</td>
                                 <td colspan="2" rowspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 79<br/>25%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 243<br/>46%
</td>
                              </tr>
                              <tr>
                                 <td colspan="5" align="left" valign="top" styleCode="Botrule Lrule Rrule">Endoscopic remission<sup>h</sup> at Week 52
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Total population
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 168<br/>8%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 511<br/>19%
</td>
                                 <td colspan="2" align="center" valign="top" styleCode="Botrule Rrule">11% <sup>e</sup>
                                    <br/>(6%, 16%)
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Without prior biologic failure
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N =  89<br/>10%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 268<br/>22%
</td>
                                 <td colspan="2" rowspan="2" align="center" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">     Prior biologic failure<sup>f</sup>
                                 </td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 79<br/>5%
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">N = 243<br/>16%
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250115"/>
                     <component>
                        <section ID="s77">
                           <id root="25f5e725-211a-4004-9682-995a787e7920"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Stool Frequency and Abdominal Pain</content>
                              </paragraph>
                              <paragraph>In CD-1, reductions in abdominal pain were observed as early as Week 6 and in stool frequency as early as Week 12 in subjects treated with OMVOH compared to placebo.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s78">
                           <id root="6ba05488-57e2-4518-8f60-9e290fc0c444"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Fatigue</content>
                              </paragraph>
                              <paragraph>In CD-1, subjects treated with OMVOH experienced a clinically meaningful improvement in fatigue, assessed by the change from baseline in the Functional Assessment of Chronic Illness Therapy Fatigue Scale (FACIT-Fatigue), at Week 12, compared to placebo-treated subjects. The effect of OMVOH to improve fatigue after 12 weeks has not been established.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s79">
                           <id root="e121ea74-20dd-4046-a0f1-4abca7a60fb1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Other Assessments at Week 12</content>
                              </paragraph>
                              <paragraph>In CD-1, a greater proportion of subjects treated with OMVOH compared to placebo achieved clinical remission (34% versus 23%) and endoscopic remission (10% versus 4%) at Week 12.
</paragraph>
                           </text>
                           <effectiveTime value="20250115"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s80">
               <id root="178d42d6-4e51-4d17-8ee3-08020342f4ec"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>OMVOH (mirikizumab-mrkz) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution for intravenous infusion or subcutaneous injection.
</paragraph>
                  <paragraph>OMVOH is supplied in indication specific packaging as:
</paragraph>
                  <table ID="t10" width="100%">
                     <caption>Table 10: Packaging Information for OMVOH
</caption>
                     <col width="29.382%" align="left"/>
                     <col width="40.410%" align="left"/>
                     <col width="16.979%" align="left"/>
                     <col width="13.228%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Presentation</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Indication</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">Package Size</content>
                           </td>
                           <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                              <content styleCode="bold">NDC Code</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">Single-dose Vial
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">300 mg/15 mL (20 mg/mL)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Ulcerative colitis and Crohn's disease<br/>
                           </td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Carton of 1
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">0002-7575-01
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">Single-dose Prefilled Pen
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">100 mg/mL + 100 mg/mL
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Ulcerative colitis
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Carton of 2
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">0002-8011-27
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">200 mg/2 mL + 100 mg/mL
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Crohn's disease<br/>
                           </td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Carton of 2<br/>(1 of each)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">0002-7717-11
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">Single-dose Prefilled Syringe
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">100 mg/mL + 100 mg/mL
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Ulcerative colitis
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Carton of 2
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">0002-8870-27
</td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule Lrule Rrule">200 mg/2 mL (100 mg/mL) + 100 mg/mL
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Crohn's disease
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">Carton of 2<br/>(1 of each)
</td>
                           <td align="center" valign="top" styleCode="Botrule Rrule">0002-7722-11
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Note to Pharmacist: The entire carton of 2 prefilled pen or 2 prefilled syringes are to be dispensed as a unit.
</paragraph>
                  <paragraph>Each 100 mg/mL single-dose prefilled pen or prefilled syringe consists of a 1 mL glass syringe with a fixed 27-gauge ½ inch needle.
</paragraph>
                  <paragraph>Each 200 mg/2 mL single-dose prefilled pen or 200 mg/2 mL (100 mg/mL) prefilled syringe consists of a 2 mL glass syringe with a fixed 27-gauge 8 mm needle.
</paragraph>
               </text>
               <effectiveTime value="20250115"/>
               <component>
                  <section ID="s81">
                     <id root="ac180d04-0771-4395-9f99-0283d1f13492"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Store refrigerated at 2°C to 8°C (36°F to 46°F).
</item>
                           <item>Do not freeze. Do not use OMVOH if it has been frozen.
</item>
                           <item>Do not shake.
</item>
                           <item>Keep OMVOH in the original carton to protect from light until the time of use.
</item>
                           <item>OMVOH is sterile and preservative-free. Discard any unused portion.
</item>
                           <item>If needed, the prefilled pen or prefilled syringe may be stored at room temperature up to 30°C (86°F) for up to 2 weeks in the original carton to protect from light. Once OMVOH has been stored at room temperature, do not return to the refrigerator. If these conditions are exceeded, OMVOH must be discarded.
</item>
                           <item>The vial, prefilled pen, and prefilled syringe are not made with dry natural rubber latex.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20250115"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s82">
               <id root="c7c155cb-14e6-4a03-a664-88a019313cb8"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypersensitivity Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to discontinue OMVOH and seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s22">5.1</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Infections</content>
                  </paragraph>
                  <paragraph>Advise patients that OMVOH may lower the ability of their immune system to fight infections and to contact their healthcare provider immediately if they develop any symptoms of infection <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s23">5.2</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Tuberculosis</content>
                  </paragraph>
                  <paragraph>Advise patients to contact their healthcare provider if they experience symptoms suggestive of TB (e.g., unexplained fever, cough, or difficulty breathing) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s24">5.3</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity</content>
                  </paragraph>
                  <paragraph>Inform patients that OMVOH may cause liver injury. Advise patients to seek immediate medical attention if they experience symptoms suggestive of liver dysfunction (e.g., unexplained rash, nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s25">5.4</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Immunizations</content>
                  </paragraph>
                  <paragraph>Advise patients that vaccination with live vaccines is not recommended during OMVOH treatment and immediately prior to or after OMVOH treatment. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Instruct patients to inform their healthcare provider that they are taking OMVOH prior to receiving a vaccination <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s26">5.5</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy</content>
                  </paragraph>
                  <paragraph>Advise patients who are exposed to OMVOH during pregnancy to contact Eli Lilly and Company <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#s40">8.1</linkHtml>)]</content>.
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration</content>
                  </paragraph>
                  <paragraph>Instruct patients in preparation and administration of OMVOH, including choosing anatomical sites for subcutaneous administration, and proper subcutaneous injection technique. Instruct patients in the technique of prefilled pen or prefilled syringe disposal <content styleCode="italics">[see Instructions for Use]</content>.
</paragraph>
                  <paragraph>Instruct ulcerative colitis patients or caregivers to administer two 100 mg prefilled pens or two 100 mg prefilled syringes to achieve the full 200 mg dose of OMVOH.
</paragraph>
                  <paragraph>Instruct Crohn's disease patients or caregivers to administer a 100 mg prefilled pen or prefilled syringe and a 200 mg prefilled pen or prefilled syringe in any order to achieve the full 300 mg dose of OMVOH.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Eli Lilly and Company, Indianapolis, IN 46285, USA<br/>US License No. 1891</content>
                  </paragraph>
                  <paragraph>Copyright © 2023, 2025, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>OMV-0005-USPI-20250122
</paragraph>
               </text>
               <effectiveTime value="20250122"/>
            </section>
         </component>
         <component>
            <section ID="s83">
               <id root="055fc33f-a405-444c-bafd-bc8eaaba8036"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <text>
                  <table width="100%">
                     <col width="33.325%" align="left"/>
                     <col width="33.325%" align="left"/>
                     <col width="7.150%" align="left"/>
                     <col width="26.200%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph styleCode="footnote">This Medication Guide has been approved by the U.S. Food and Drug Administration.
</paragraph>
                           </td>
                           <td align="right" valign="top">
                              <paragraph styleCode="footnote">Revised:01/2025
</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top">
                              <paragraph styleCode="footnote">OMV-0003-MG-20250115
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="4" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Medication Guide</content>
                              <br/>OMVOH<sup>TM</sup> (ahm-VOH)<br/>(mirikizumab-mrkz)<br/>injection, for intravenous or subcutaneous use
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <paragraph ID="p01">
                                 <content styleCode="bold">What is the most important information I should know about OMVOH?</content>
                                 <br/>
                                 <content styleCode="bold">OMVOH can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Serious allergic reactions.</content> OMVOH may cause serious allergic reactions that may need to be treated in a hospital and may be life-threatening. Stop using OMVOH and get emergency medical help right away if you develop any of the following symptoms of a serious allergic reaction:<table width="100%" styleCode="Noautorules">
                                       <col width="39.500%" align="left"/>
                                       <col width="27.300%" align="left"/>
                                       <col width="33.200%" align="left"/>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>fainting, dizziness, feeling lightheaded (low blood pressure)
</item>
                                                   <item>swelling of your face, eyelids, lips, mouth, tongue, throat, or trouble swallowing
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>trouble breathing, throat tightening or wheezing
</item>
                                                   <item>chest tightness
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>fast heartbeat or pounding in your chest (tachycardia)
</item>
                                                   <item>severe itching, hives, or redness all over your body
</item>
                                                   <item>sweating
</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Infections.</content> OMVOH may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should not start treatment with OMVOH until your infection is gone.<list listType="unordered" styleCode="Circle">
                                       <item>Before starting your treatment with OMVOH, your healthcare provider should test you for tuberculosis (TB).
</item>
                                       <item>If your healthcare provider feels that you are at risk for TB, you may be treated with medicine for TB before you begin treatment with OMVOH.
</item>
                                       <item>Your healthcare provider should watch you closely for signs and symptoms of TB while you are being treated with OMVOH and after treatment.
</item>
                                       <item>Before starting OMVOH, tell your healthcare provider if you think you have an infection or have symptoms of an infection such as:<table width="100%" styleCode="Noautorules">
                                             <col width="34.155%" align="left"/>
                                             <col width="32.922%" align="left"/>
                                             <col width="32.922%" align="left"/>
                                             <tbody>
                                                <tr>
                                                   <td align="left" valign="middle">
                                                      <list listType="unordered" styleCode="Disc">
                                                         <item>fever, sweating, or chills
</item>
                                                         <item>muscle aches and pain
</item>
                                                         <item>cough or shortness of breath
</item>
                                                         <item>blood in your mucus (phlegm)
</item>
                                                      </list>
                                                   </td>
                                                   <td align="left" valign="middle">
                                                      <list listType="unordered" styleCode="Disc">
                                                         <item>flu-like symptoms
</item>
                                                         <item>headache
</item>
                                                         <item>warm, red, or painful skin or sores on your body
</item>
                                                      </list>
                                                   </td>
                                                   <td align="left" valign="middle">
                                                      <list listType="unordered" styleCode="Disc">
                                                         <item>diarrhea or stomach pain
</item>
                                                         <item>weight loss
</item>
                                                         <item>nausea or vomiting
</item>
                                                         <item>pain during urination
</item>
                                                      </list>
                                                   </td>
                                                </tr>
                                             </tbody>
                                          </table>
                                       </item>
                                    </list>
                                    <paragraph>After starting OMVOH, tell your healthcare provider right away if you have any symptoms of an infection.
</paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Liver problems.</content> OMVOH may cause liver problems. Your healthcare provider will do blood tests to check your liver enzyme and bilirubin levels before treatment, for at least 24 weeks during treatment, and possibly after treatment with OMVOH. Your healthcare provider may hold or stop your treatment if needed. Tell your healthcare provider right away if you develop any signs and symptoms of liver problems, including:<table width="100%" styleCode="Noautorules">
                                       <col width="46.450%" align="left"/>
                                       <col width="53.550%" align="left"/>
                                       <tbody>
                                          <tr>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>unexplained rash
</item>
                                                   <item>nausea
</item>
                                                   <item>vomiting
</item>
                                                   <item>stomach-area (abdominal) pain
</item>
                                                </list>
                                             </td>
                                             <td align="left" valign="top">
                                                <list listType="unordered" styleCode="Circle">
                                                   <item>feeling tired
</item>
                                                   <item>loss of appetite
</item>
                                                   <item>yellowing of the skin or the whites of your eyes
</item>
                                                   <item>dark urine
</item>
                                                </list>
                                             </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is OMVOH?</content>
                              <br/>OMVOH is a prescription medicine used to treat:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>adults with moderately to severely active ulcerative colitis
</item>
                                 <item>adults with moderately to severely active Crohn's disease
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">It is not known if OMVOH is safe and effective in children.
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Do not use OMVOH if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are allergic to mirikizumab-mrkz or any of the ingredients in OMVOH. See the end of this Medication Guide for a complete list of ingredients in OMVOH.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before you use OMVOH, tell your healthcare provider about all your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have any of the conditions or symptoms listed in the section “<content styleCode="bold">
                                       <linkHtml href="#p01">What is the most important information I should know about OMVOH?</linkHtml>
                                    </content>”
</item>
                                 <item>have recently received or are scheduled to receive any vaccinations. Medicines that affect your immune system may increase your risk of getting an infection after receiving live vaccines.<list listType="unordered" styleCode="Circle">
                                       <item>You should be brought up to date with all age required vaccines before starting treatment with OMVOH.
</item>
                                       <item>You should avoid receiving ‘live’ vaccines right before, during, or right after treatment with OMVOH. Tell your healthcare provider that you are taking OMVOH before receiving a vaccine.
</item>
                                    </list>
                                 </item>
                                 <item>are pregnant, or plan to become pregnant. It is not known if OMVOH will harm your unborn baby. There will be a pregnancy registry to collect information about women who are exposed to OMVOH during pregnancy. If you become pregnant while taking OMVOH, you are encouraged to report your pregnancy to Eli Lilly and Company at 1-800-Lilly-Rx (1-800-545-5979).
</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if OMVOH passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby while using OMVOH.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I use OMVOH?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use OMVOH exactly as your healthcare provider tells you to.
</item>
                                 <item>You will receive your first 3 doses of OMVOH through a vein in your arm (intravenous infusion) in a healthcare facility by a healthcare provider every 4 weeks.<list listType="unordered" styleCode="Circle">
                                       <item>For ulcerative colitis, each infusion will last about 30 minutes.
</item>
                                       <item>For Crohn's disease, each infusion will last about 90 minutes.
</item>
                                    </list>
                                 </item>
                                 <item>After your intravenous infusions, you will continue to receive OMVOH as an injection under the skin (subcutaneous injection) every 4 weeks as described below.
</item>
                                 <item>
                                    <content styleCode="bold">See the detailed Instructions for Use that comes with OMVOH for information on how to prepare and inject a dose of OMVOH, and how to properly throw away (dispose of) used OMVOH prefilled pens or prefilled syringes.</content>
                                 </item>
                                 <item>OMVOH comes as 2 different types of 1-time use devices:<list listType="unordered" styleCode="Circle">
                                       <item>a prefilled pen,
</item>
                                       <item>a prefilled syringe.<paragraph>Your healthcare provider will decide which type of device is best for you.
</paragraph>
                                       </item>
                                    </list>
                                 </item>
                                 <item>For your full dose, you will need 2 injections either with 2 prefilled pens or 2 prefilled syringes. Inject 1 OMVOH prefilled pen or prefilled syringe followed right away by the other OMVOH prefilled pen or prefilled syringe.<list listType="unordered" styleCode="Circle">
                                       <item>For ulcerative colitis, you will need to inject two 100 mg/mL prefilled pens or prefilled syringes.
</item>
                                       <item>For Crohn's disease, you will need to inject one 100 mg/mL prefilled pen or prefilled syringe and one 200 mg/2 mL prefilled pen or 200 mg/2 mL (100 mg/mL) prefilled syringe in any order.
</item>
                                       <item>The 200 mg/2 mL prefilled pen and 200 mg/2 mL (100 mg/mL) prefilled syringe are <content styleCode="bold">only</content> for treatment of Crohn's disease.
</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Injecting OMVOH under your skin:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>OMVOH is intended for use under the guidance and supervision of your healthcare provider. If your healthcare provider decides that you or a caregiver may give your injections of OMVOH at home, you should receive training on the correct way to prepare and inject OMVOH. <content styleCode="bold">Do not</content> try to inject OMVOH yourself until you or your caregiver have been shown how to inject OMVOH.
</item>
                                       <item>Inject OMVOH under the skin in your stomach area (abdomen), upper legs (thighs), or back of the upper arms.
</item>
                                       <item>
                                          <content styleCode="bold">Do not</content> give an injection in an area that is tender, bruised, red, or hard.
</item>
                                       <item>Use a different injection site each time you use OMVOH.
</item>
                                    </list>
                                 </item>
                                 <item>If you miss a dose of OMVOH, inject the missed dose as soon as possible. Then take your next dose in 4 weeks. If you have questions about how often you should use OMVOH, talk to your healthcare provider.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of OMVOH?</content>
                              <br/>
                              <content styleCode="bold">OMVOH can cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">“<linkHtml href="#p01">What is the most important information I should know about OMVOH?</linkHtml>”</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of OMVOH in people treated for ulcerative colitis include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>upper respiratory infections
</item>
                                 <item>injection site reactions
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>joint pain
</item>
                                 <item>headache
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>rash
</item>
                                 <item>herpes viral infections
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of OMVOH in people treated for Crohn's disease include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>upper respiratory infections
</item>
                                 <item>injection site reactions
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>elevated liver blood tests
</item>
                                 <item>headache
</item>
                              </list>
                           </td>
                           <td colspan="2" align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>joint pain
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">Tell your healthcare provider if you have any side effect that bothers you or that does not go away.<br/>These are not all the possible side effects of OMVOH. For more information, ask your healthcare provider or pharmacist.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store OMVOH?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>In the original carton, store OMVOH prefilled pens and prefilled syringes in a refrigerator between 36°F to 46°F (2°C to 8°C).
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze. <content styleCode="bold">Do not</content> use OMVOH if it has been frozen.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> shake.
</item>
                                 <item>Keep OMVOH in the original carton to protect from light until the time of use.
</item>
                                 <item>If needed, your prefilled pens or prefilled syringes may be stored at room temperature for up to 2 weeks in the original carton. <content styleCode="bold">Do not</content> store above 86°F (30°C).<list listType="unordered" styleCode="Circle">
                                       <item>When OMVOH has been stored at room temperature, <content styleCode="bold">do not</content> return it to the refrigerator.
</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not</content> use and throw away (dispose of) your prefilled pens and prefilled syringes if they:<list listType="unordered" styleCode="Circle">
                                       <item>have been frozen.
</item>
                                       <item>have been shaken.
</item>
                                       <item>have not been protected from light in the original carton.
</item>
                                       <item>have been stored at room temperature more than 2 weeks.
</item>
                                    </list>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Keep OMVOH and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of OMVOH.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use OMVOH for a condition for which it was not prescribed. Do not give OMVOH to other people, even if they have the same symptoms that you have. It may harm them.<br/>You can ask your pharmacist or healthcare provider for information about OMVOH that is written for health professionals.
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in OMVOH?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> mirikizumab-mrkz.<br/>
                              <content styleCode="bold">Inactive ingredients:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Intravenous infusion:</content> anhydrous citric acid, polysorbate 80, sodium chloride, sodium citrate, and Water for Injection.
</item>
                                 <item>
                                    <content styleCode="bold">Subcutaneous injection for ulcerative colitis and Crohn's disease:</content> histidine, L-histidine hydrochloride monohydrate, mannitol, polysorbate 80, sodium chloride, and Water for Injection.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top" styleCode="Botrule Lrule Rrule">OMVOH prefilled pens and prefilled syringes are not made with dry natural rubber latex.<br/>OMVOH<sup>TM</sup> is a trademark of Eli Lilly and Company.<br/>
                              <content styleCode="bold">Eli Lilly and Company, Indianapolis, IN 46285, USA</content>
                              <br/>
                              <content styleCode="bold">US License No. 1891</content>
                              <br/>Copyright © 2023, 2025, Eli Lilly and Company. All rights reserved.<br/>For more information, go to www.OMVOH.com or call 1-800-545-5979.
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250115"/>
            </section>
         </component>
         <component>
            <section ID="s84">
               <id root="7092b6a4-fca2-4248-bece-aa14717c684e"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Omvoh 200 mg Dose Prefilled Pen Instructions for Use - Ulcerative Colitis </title>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">OMVOH</content>
                              <content styleCode="bold">
                                 <sup>TM
</sup>
                              </content>
                              <content styleCode="bold">(ahm-VOH)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">(mirikizumab-mrkz)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">injection, for subcutaneous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">100 mg/mL prefilled Pens</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <content styleCode="bold">This Instructions for Use contains information on how to inject OMVOH.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f01" referencedObject="mm01"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Before you use the OMVOH prefilled Pens, read and carefully follow all the step-by-step instructions. Two injections are required for a full dose.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Important information you need to know before injecting OMVOH:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">For injections under the skin (subcutaneous injection) only.</content>
                                 </item>
                                 <item>Your healthcare provider should show you how to prepare and inject OMVOH using the prefilled Pen. <content styleCode="bold">Do not</content> inject yourself or someone else until you have been shown how to inject OMVOH.
</item>
                                 <item>Keep this Instructions for Use and read it as needed.
</item>
                                 <item>
                                    <content styleCode="bold">2 OMVOH injections are required for a full dose.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Inject 1 OMVOH prefilled Pen followed right away by the other OMVOH prefilled Pen.</content>
                                 </item>
                                 <item>Each OMVOH prefilled Pen is for <content styleCode="bold">1-time use only.</content>
                                 </item>
                                 <item>The OMVOH prefilled Pen contains glass parts. Handle it carefully. If you drop it on a hard surface do not use it. Use a new OMVOH prefilled Pen for your injection.
</item>
                                 <item>Your healthcare provider may help you decide where on your body to inject your dose. You can also read the <content styleCode="bold">Choose your injection site</content> section of these instructions to help you choose which area can work best for you.
</item>
                                 <item>If you have vision or hearing problems, <content styleCode="bold">do not</content> use OMVOH prefilled Pen without help from a caregiver.
</item>
                                 <item>See <content styleCode="bold">
													Storing OMVOH Prefilled Pens
												</content> for important storage information.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Before you use the OMVOH prefilled Pens, read and carefully follow all the step-by-step instructions.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Parts of the OMVOH prefilled Pen</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top"/>
                        </tr>
                        <tr>
                           <td align="center" valign="middle">
                              <renderMultiMedia ID="f02" referencedObject="mm02"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">Important:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 OMVOH injections are required for a full dose.
</item>
                                 <item>Inject 1 OMVOH prefilled Pen followed right away by the other OMVOH prefilled Pen.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="35.050%" align="left"/>
                     <col width="64.950%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">2 injections are required for a full dose. Inject one prefilled Pen immediately followed by the other prefilled Pen.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Preparing to inject OMVOH</content>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="5" align="left" valign="top">
                              <content styleCode="bold">Take the prefilled Pens from the refrigerator</content>
                           </td>
                           <td align="left" valign="top">Take 2 OMVOH prefilled Pens from the refrigerator.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Leave the gray base caps on until you are ready to inject.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Leave the prefilled Pens at room temperature for 30 minutes before injecting.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> microwave the prefilled Pens, or run hot water over them, or leave them in direct sunlight.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> shake the prefilled Pens.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Gather supplies</content>
                           </td>
                           <td align="left" valign="top">Supplies:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 alcohol wipes
</item>
                                 <item>2 cotton balls or pieces of gauze
</item>
                                 <item>1 sharps container (see <content styleCode="bold">Throwing away (disposing of) OMVOH Prefilled Pens</content>)
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Inspect the prefilled Pens and the medicine<br/>
                                 <br/>
                                 <br/>                    Expiration date<br/>
                              </content>
                              <renderMultiMedia ID="f03" referencedObject="mm03"/>
                           </td>
                           <td align="left" valign="top">Make sure you have the right medicine. The medicine inside should be clear. It may be colorless to slightly yellow to slightly brown.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> use the prefilled Pens and throw away (dispose of) as directed by your healthcare provider or pharmacist if:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>one or both prefilled Pens look damaged
</item>
                                 <item>the medicine is cloudy, is discolored, or has particles
</item>
                                 <item>the expiration date printed on the label has passed
</item>
                                 <item>the medicine is frozen
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Prepare for injection</content>
                           </td>
                           <td align="left" valign="top">Wash your hands with soap and water before you inject OMVOH.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Choose your injection site</content>
                           </td>
                           <td align="left" valign="top">Your healthcare provider can help you choose the injection site that is best for you.
</td>
                        </tr>
                        <tr>
                           <td rowspan="2" align="left" valign="top">
                              <br/>
                              <br/>
                              <renderMultiMedia ID="f04" referencedObject="mm04"/>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">You or another person</content> may inject the medicine into your stomach area (abdomen). <content styleCode="bold">Do not</content> inject within 2 inches of the belly button (navel).
</item>
                                 <item>
                                    <content styleCode="bold">You or another person</content> may inject the medicine in the front of your thighs. This area should be at least 2 inches above the knee and 2 inches below the groin.
</item>
                                 <item>
                                    <content styleCode="bold">Another person</content> may give you the injection in the back of your upper arm.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject in the exact same spot every time. For example, if your first injection was in your abdomen, your second injection (to complete a full dose) should be in another spot in your abdomen, or upper arm, or thigh.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into areas where the skin is tender, bruised, red, or hard.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Clean the injection sites with an alcohol wipe. Let the injection sites dry before you inject the medicine.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="7.420%" align="left"/>
                     <col width="5.040%" align="left"/>
                     <col width="42.840%" align="left"/>
                     <col width="17.760%" align="left"/>
                     <col width="26.940%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Injecting OMVOH</content>
                           </td>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td rowspan="3" align="left" valign="top">1
</td>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">Uncap the prefilled Pen</content>
                           </td>
                           <td colspan="2" rowspan="3" align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f05" referencedObject="mm05"/>
                              <renderMultiMedia ID="f06" referencedObject="mm06"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top">
                              <br/>
                              <br/>
                              <renderMultiMedia ID="f07" referencedObject="mm07"/>
                           </td>
                           <td align="left" valign="top">
                              <br/>Make sure the prefilled Pen is <content styleCode="bold">locked</content>.<br/>
                              <br/>
                              <br/>Leave the gray base cap on until you are ready to inject.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="bottom">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Twist off the gray base cap and throw it away in your household trash.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the gray base cap back on. This could damage the needle.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the needle.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="2" align="left" valign="top"> 
</td>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td rowspan="2" align="left" valign="top">2
</td>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">Place and unlock</content>
                           </td>
                           <td colspan="2" rowspan="3" align="left" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f08" referencedObject="mm08"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" rowspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <paragraph>Place and hold the clear base flat and firmly against the skin.<br/>
                                       <renderMultiMedia ID="f07a" referencedObject="mm07a"/>Keep the clear base on the skin, then turn the lock ring to the <content styleCode="bold">unlock</content> position.
</paragraph>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="2" align="left" valign="top"> 
</td>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td rowspan="3" align="left" valign="top">3
</td>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">Press and hold for up to 10 seconds</content>
                           </td>
                           <td colspan="2" rowspan="2" align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f09" referencedObject="mm09"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" rowspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Press and hold the blue injection button. You will hear a loud click (injection started).
</item>
                                 <item>
                                    <content styleCode="bold">Keep holding the clear base firmly against the skin.</content> You will hear a second loud click in about 10 seconds after the first one (injection completed).
</item>
                                 <item>You will know the injection is complete when the gray plunger is visible.
</item>
                                 <item>Remove the prefilled Pen from the skin.
</item>
                                 <item>If you have bleeding at the injection site, press a cotton ball or gauze over the injection site.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site, as this may cause bruising.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f10" referencedObject="mm10"/>
                           </td>
                           <td align="left" valign="middle"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">4</content>
                           </td>
                           <td colspan="4" rowspan="3" align="left" valign="top">
                              <content styleCode="bold">Inject the second prefilled Pen</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Choose</content> a new injection site at least 2 inches away and clean it.
</item>
                                 <item>With your second prefilled Pen, <content styleCode="bold">repeat steps 1 to 3</content> right away after your first injection.
</item>
                                 <item>
                                    <content styleCode="bold">You must inject 2 prefilled Pens to complete your full 200 mg dose.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="6.567%" align="left"/>
                     <col width="53.867%" align="left"/>
                     <col width="39.567%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <paragraph ID="p03">
                                 <content styleCode="bold">Throwing away (disposing of) OMVOH Prefilled Pens</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Throw away the used prefilled Pens</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Put the used OMVOH prefilled Pens in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the OMVOH prefilled Pens in your household trash.
</item>
                              </list>
                           </td>
                           <td align="center" valign="bottom">
                              <br/>
                              <renderMultiMedia ID="f11" referencedObject="mm11"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>made of a heavy-duty plastic,
</item>
                                 <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                                 <item>upright and stable during use,
</item>
                                 <item>leak-resistant, and
</item>
                                 <item>properly labeled to warn of hazardous waste inside the container.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be local laws about how you should throw away needles and syringes.
</item>
                                 <item>For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="5.026%" align="left"/>
                     <col width="45.986%" align="left"/>
                     <col width="14.754%" align="left"/>
                     <col width="34.234%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="4" align="left" valign="top">
                              <content styleCode="bold">Commonly asked questions</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if I let my prefilled Pen warm up for longer than 30 minutes before injecting?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">Your prefilled Pen can stay at room temperature up to 86°F (30°C) for up to 2 weeks.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if I see air bubbles in the prefilled Pen?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="bottom">It is normal to have air bubbles in the prefilled Pen. They will not harm you or affect your dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid on the tip of the needle when I remove the gray base cap?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="bottom">It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if I unlocked the prefilled Pen and pressed the blue injection button before I twisted off the gray base cap?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Do not</content> remove the gray base cap. Throw away (dispose of) the prefilled Pen and get a new one.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Do I need to hold the blue injection button down until the injection is complete?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">You do not need to hold the blue injection button down, but it may help you keep the prefilled Pen steady and firm against your skin.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if the needle did not retract after my injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Do not</content> touch the needle or replace the gray base cap. Store the prefilled Pen in a safe place to avoid an accidental needlestick and contact 1-800-Lilly-Rx (1-800-545-5979) for instructions on how to return the prefilled Pen.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid or blood on my skin after my injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">This is normal. Press a cotton ball or gauze over the injection site. <content styleCode="bold">Do not</content> rub the injection site.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if I heard more than 2 clicks during my injection – 2 loud clicks and a soft one. Did I get my complete injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">Some patients may hear a soft click right before the second loud click. That is the normal operation of the prefilled Pen. <content styleCode="bold">Do not</content> remove the prefilled Pen from your skin until you hear the second loud click.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">How can I tell if my injection is complete?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">After you press the blue injection button, you will hear 2 loud clicks. The second loud click tells you that your injection is complete. You will also see the gray plunger at the top of the clear base.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top">
                              <content styleCode="bold">If you have more questions about how to use the OMVOH prefilled Pen:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td rowspan="2" align="left" valign="bottom">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Call your healthcare provider
</item>
                                 <item>Call 1-800-Lilly-Rx (1-800-545-5979)
</item>
                                 <item>Visit www.OMVOH.com
</item>
                              </list>
                           </td>
                           <td rowspan="2" align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f12" referencedObject="mm12"/>
                           </td>
                           <td rowspan="2" align="left" valign="middle">Scan this code to launch www.OMVOH.com
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.000%" align="left"/>
                     <col width="50.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <paragraph ID="p02">
                                 <content styleCode="bold">Storing OMVOH Prefilled Pens</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">Refrigeration</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>In the original carton, store your prefilled Pens in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC) until the expiration date.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze. <content styleCode="bold">Do not</content> use OMVOH if it has been frozen.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <br/>
                              <br/>
                              <br/>
                              <content styleCode="bold">Room temperature</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>If needed, your prefilled Pens may be stored at room temperature for up to 2 weeks in the original carton. <content styleCode="bold">Do not</content> store above 86°F (30°C).
</item>
                                 <item>When OMVOH has been stored at room temperature, do not return it to the refrigerator.
</item>
                                 <item>Throw away (dispose of) OMVOH if not used within 2 weeks at room temperature.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Protect your prefilled Pens from light until use.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <br/>
                              <content styleCode="bold">Do not</content> use the prefilled Pens and throw away (see <content styleCode="bold">
											Throwing away (disposing of) OMVOH Prefilled Pens</content>) if they have been:
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Frozen
</item>
                                 <item>microwaved
</item>
                                 <item>warmed with hot water
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>left in direct sunlight
</item>
                                 <item>shaken<br/>
                                    <br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Keep OMVOH and all medicines out of the reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Read the Medication Guide for OMVOH inside this box to learn more about your medicine.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Eli Lilly and Company</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Indianapolis, IN 46285, USA</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">US License Number 1891</content>
                  </paragraph>
                  <paragraph>OMVOH™ is a trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright © 2023, 2025, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>Revised: January 2025
</paragraph>
                  <paragraph>The OMVOH prefilled Pen meets the current dose accuracy and functional requirements of ISO 11608-1 and 11608-5.
</paragraph>
                  <paragraph>OMV-0004-IFU-PEN-20250115
</paragraph>
               </text>
               <effectiveTime value="20250115"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-1-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm02">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-2-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm03">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-3-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm04">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-ifu-injection-sites-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm05">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-4-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm06">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-5-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm07">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-ai-lock.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm07a">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-ai-unlock.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm08">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-6-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm09">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-7-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm10">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-8-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm11">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-ai-9-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm12">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-qr-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s85">
               <id root="431b894a-249d-4294-841d-257fd716f08e"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Omvoh 200 mg Dose Prefilled Syringe Instructions for Use - Ulcerative Colitis </title>
               <text>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">OMVOH</content>
                              <content styleCode="bold">
                                 <sup>TM
</sup>
                              </content>
                              <content styleCode="bold">(ahm-VOH)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">(mirikizumab-mrkz)</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">injection, for subcutaneous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">100 mg/mL prefilled syringe</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">This Instructions for Use contains information on how to inject OMVOH.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="bottom">
                              <br/>
                              <renderMultiMedia ID="f28" referencedObject="mm28"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Before you use the OMVOH prefilled syringes, read and carefully follow all the step-by-step instructions. Two injections are required for a full dose.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Important information you need to know before injecting OMVOH:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">For injection under the skin (subcutaneous injection) only.</content>
                                 </item>
                                 <item>Your healthcare provider should show you how to prepare and inject OMVOH using the prefilled syringes. <content styleCode="bold">Do not</content> inject yourself or someone else until you have been shown how to inject OMVOH.
</item>
                                 <item>Keep this Instructions for Use and read it as needed.
</item>
                                 <item>
                                    <content styleCode="bold">2 OMVOH injections are required for a full dose.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Inject 1 OMVOH prefilled syringe followed right away by the other OMVOH prefilled syringe.</content>
                                 </item>
                                 <item>Each OMVOH prefilled syringe is for <content styleCode="bold">1-time use only. Do not</content> share or reuse your OMVOH prefilled syringe. You may give or get an infection.
</item>
                                 <item>The OMVOH prefilled syringes contain glass parts. Handle it carefully. If you drop it on a hard surface, do not use it. Use a new OMVOH prefilled syringe for your injection.
</item>
                                 <item>Your healthcare provider may help you decide where on your body to inject your dose. You can also read the <content styleCode="bold">Choose your injection site</content> section of these instructions to help you choose which area can work best for you.
</item>
                                 <item>If you have vision problems, <content styleCode="bold">do not</content> use OMVOH prefilled syringes without help from a caregiver.
</item>
                                 <item>See <content styleCode="bold">
													Storing OMVOH prefilled syringes
												</content> for important storage information.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Before you use OMVOH prefilled syringes, read and carefully follow all the step-by-step instructions.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Parts of the OMVOH prefilled syringe</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="bottom">
                              <br/>
                              <renderMultiMedia ID="f29" referencedObject="mm29"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top" styleCode="Botrule"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Important:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 OMVOH injections are required for a full dose.
</item>
                                 <item>Inject 1 OMVOH prefilled syringe followed right away by the other OMVOH prefilled syringe.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">2 injections are required for a full dose. Inject one prefilled syringe immediately followed by the other prefilled syringe.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="37.550%" align="left"/>
                     <col width="62.450%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">Preparing to inject OMVOH</content>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="5" align="left" valign="top">
                              <content styleCode="bold">Take the prefilled syringes from the refrigerator</content>
                           </td>
                           <td align="left" valign="top">Take 2 OMVOH prefilled syringes from the refrigerator.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Leave the needle caps on until you are ready to inject.</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">Leave the prefilled syringes at room temperature for 30 minutes before injecting.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> microwave the prefilled syringes, or run hot water over them, or leave them in direct sunlight.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> shake the prefilled syringes.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Gather supplies</content>
                           </td>
                           <td align="left" valign="top">Supplies:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 alcohol wipes
</item>
                                 <item>2 cotton balls or pieces of gauze
</item>
                                 <item>1 sharps container (see <content styleCode="bold">Throwing away (disposing of) OMVOH prefilled syringes</content>)
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="2" align="left" valign="top">
                              <content styleCode="bold">Inspect the prefilled syringes and the medicine<br/>
                                 <br/>
                                 <br/>                    Expiration date<br/>
                              </content>
                              <renderMultiMedia ID="f30" referencedObject="mm30"/>
                           </td>
                           <td align="left" valign="top">Make sure you have the right medicine. The medicine inside should be clear. It may be colorless to slightly yellow to slightly brown.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> use the prefilled syringes and throw away (dispose of) as directed by your healthcare provider or pharmacist if:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>one or both prefilled syringes look damaged
</item>
                                 <item>the medicine is cloudy, is discolored, or has particles
</item>
                                 <item>the expiration date printed on the label has passed
</item>
                                 <item>the medicine is frozen
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Prepare for injection</content>
                           </td>
                           <td align="left" valign="top">Wash your hands with soap and water before you inject OMVOH.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Choose your injection site</content>
                           </td>
                           <td align="left" valign="top">Your healthcare provider can help you choose the injection site that is best for you.
</td>
                        </tr>
                        <tr>
                           <td rowspan="2" align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f31" referencedObject="mm31"/>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">You or another person</content> may inject the medicine into your stomach area (abdomen). <content styleCode="bold">Do not</content> inject within 2 inches of the belly button (navel).
</item>
                                 <item>
                                    <content styleCode="bold">You or another person</content> may inject the medicine in the front of your thighs. This area should be at least 2 inches above the knee and 2 inches below the groin.
</item>
                                 <item>
                                    <content styleCode="bold">Another person</content> may give you the injection in the back of your upper arm.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject in the exact same spot every time. For example, if your first injection was in your abdomen, your second injection (to complete a full dose) should be in another spot in your abdomen.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> inject into areas where the skin is tender, bruised, red, or hard.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Clean the injection sites with an alcohol wipe. Let the injection sites dry before you inject the medicine.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="3.850%" align="left"/>
                     <col width="8.383%" align="left"/>
                     <col width="45.150%" align="left"/>
                     <col width="8.383%" align="left"/>
                     <col width="23.583%" align="left"/>
                     <col width="10.650%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="6" align="left" valign="top">
                              <content styleCode="bold">Injecting OMVOH</content>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="3" align="left" valign="top">
                              <content styleCode="bold">1</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Uncap the prefilled syringe</content>
                           </td>
                           <td colspan="2" rowspan="3" align="center" valign="bottom">
                              <br/>
                              <renderMultiMedia ID="f32a" referencedObject="mm32"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Leave the needle cap on until you are ready to inject.</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Pull the needle cap off and throw it away in your household trash.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the needle cap back on. You could damage the needle or stick yourself by accident.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> touch the needle.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"> 
</td>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">2</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Insert</content>
                           </td>
                           <td colspan="2" rowspan="2" align="center" valign="bottom">
                              <br/>
                              <renderMultiMedia ID="f33a" referencedObject="mm33"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Gently pinch and hold a fold of skin where you will inject.</content>
                                 </item>
                                 <item>Insert the needle at a 45-degree angle.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold"> </content>
                           </td>
                           <td colspan="2" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td rowspan="3" align="left" valign="top">
                              <content styleCode="bold">3</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Inject</content>
                           </td>
                           <td colspan="2" rowspan="2" align="center" valign="bottom">
                              <renderMultiMedia ID="f34a" referencedObject="mm34"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Slowly push on the blue thumb pad to push the plunger all the way in until all the medicine is injected.
</item>
                                 <item>The gray syringe plunger should be pushed all the way to the needle end of the syringe.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>You should see the blue plunger rod show through the syringe body when the injection is complete as shown.
</item>
                                 <item>Remove the needle from your skin and gently let go of your skin.
</item>
                                 <item>If you have bleeding at the injection site, press a cotton ball or gauze over the injection site.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> rub the injection site, as this may cause bruising.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> put the needle cap back on the prefilled syringe.
</item>
                              </list>
                           </td>
                           <td align="center" valign="middle">
                              <renderMultiMedia ID="f35a" referencedObject="mm35"/>
                           </td>
                           <td align="left" valign="middle"/>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="7.797%" align="left"/>
                     <col width="10%" align="left"/>
                     <col width="91.603%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top">4
</td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Inject the second prefilled syringe</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Choose</content> a new injection site at least 2 inches away and clean it.
</item>
                                 <item>With your second prefilled syringe, <content styleCode="bold">repeat steps 1 to 3</content> right away after your first injection
</item>
                                 <item>
                                    <content styleCode="bold">You must inject 2 prefilled syringes to complete your full 200 mg dose.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="7.433%" align="left"/>
                     <col width="53.900%" align="left"/>
                     <col width="38.667%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">Throwing away (disposing of) OMVOH prefilled syringes</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">Throw away the used prefilled syringes</content>
                           </td>
                           <td rowspan="2" align="center" valign="middle">
                              <renderMultiMedia ID="f36" referencedObject="mm36"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Put the used OMVOH prefilled syringes in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the OMVOH prefilled syringes in your household trash.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="2" align="left" valign="top">
                              <list listType="unordered" styleCode="Circle">
                                 <item>made of a heavy-duty plastic,
</item>
                                 <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                                 <item>upright and stable during use,
</item>
                                 <item>leak-resistant, and
</item>
                                 <item>properly labeled to warn of hazardous waste inside the container.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away needles and syringes.
</item>
                                 <item>For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="4.200%" align="left"/>
                     <col width="47.950%" align="left"/>
                     <col width="21.750%" align="left"/>
                     <col width="26.100%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="4" align="left" valign="top">
                              <content styleCode="bold">Commonly asked questions</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if I let my OMVOH prefilled syringe warm up for longer than 30 minutes before injecting?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">Your prefilled syringe can stay at room temperature up to 86°F (30°C) for up to 2 weeks.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if I see air bubbles in the OMVOH prefilled syringe?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="bottom">It is normal to have air bubbles in the prefilled syringe. They will not harm you or affect your dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="bottom">It is okay to see a drop of liquid on the tip of the needle. This will not harm you or affect your dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if I cannot push in the plunger?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">If the plunger is stuck or damaged:
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="bottom"/>
                           <td colspan="3" align="left" valign="bottom">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> continue to use the prefilled syringe
</item>
                                 <item>Remove the needle from your skin
</item>
                                 <item>Throw away (dispose of) the prefilled syringe and get a new one
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid or blood on my skin after my injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">This is normal. Press a cotton ball or gauze over the injection site. <content styleCode="bold">Do not</content> rub the injection site.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">
                              <content styleCode="bold">How can I tell if my injection is complete?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">A.</content>
                           </td>
                           <td colspan="3" align="left" valign="top">When your injection is complete:
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="bottom"/>
                           <td colspan="3" align="left" valign="bottom">
                              <list listType="unordered" styleCode="Disc">
                                 <item>The blue plunger rod should show through the body of the syringe.
</item>
                                 <item>The gray syringe plunger should be pushed all the way to the needle end of the syringe.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="3" align="left" valign="top"> 
</td>
                        </tr>
                        <tr>
                           <td colspan="4" align="left" valign="top">
                              <content styleCode="bold">If you have more questions about how to use the OMVOH prefilled syringe:</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="bottom"/>
                           <td align="left" valign="bottom">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Call your healthcare provider
</item>
                                 <item>Call 1-800-LillyRx (1-800-545-5979)
</item>
                                 <item>Visit www.OMVOH.com
</item>
                              </list>
                           </td>
                           <td align="center" valign="bottom">
                              <renderMultiMedia ID="f37" referencedObject="mm37"/>
                           </td>
                           <td align="left" valign="middle">Scan this code to launch www.OMVOH.com
</td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <paragraph ID="p08">
                                 <content styleCode="bold">Storing OMVOH prefilled syringes</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store your prefilled syringes in the refrigerator between 36ºF to 46ºF (2ºC to 8ºC).
</item>
                                 <item>If needed, your prefilled syringes may be stored at room temperature for up to 2 weeks. <content styleCode="bold">Do not</content> store above 86°F (30°C). Throw away (dispose of) OMVOH if not used within 2 weeks at room temperature. When OMVOH has been stored at room temperature, do not return it to the refrigerator.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> freeze your prefilled syringes.
</item>
                                 <item>Store your prefilled syringes in the original carton to protect from light until use.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> microwave your prefilled syringes, or run hot water over them, or leave them in direct sunlight.
</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> shake your prefilled syringes.
</item>
                                 <item>Throw away (dispose of) your prefilled syringes if any of the above conditions are not followed.
</item>
                                 <item>
                                    <content styleCode="bold">Keep your prefilled syringes and all medicines out of the sight and reach of children.</content>
                                 </item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Read the Medication Guide for OMVOH inside this box to learn more about your medicine.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:<br/>Eli Lilly and Company<br/>Indianapolis, IN 46285, USA<br/>US License Number 1891</content>
                  </paragraph>
                  <paragraph>OMVOH<sup>TM</sup> is a trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright © 2024, 2025, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>Revised: January 2025
</paragraph>
                  <paragraph>OMV-0002-IFU-PFS-20250115
</paragraph>
               </text>
               <effectiveTime value="20250115"/>
               <component>
                  <observationMedia ID="mm28">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm29">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-2-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm30">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm31">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-ifu-injection-sites-v2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm32">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm33">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm34">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm35">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm36">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm37">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-qr-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s86">
               <id root="7b86d586-2d52-4b99-bc59-82d06ff34267"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Omvoh 300 mg Dose Prefilled Pen Instructions for Use - Crohns Disease </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">OMVOH</content>
                     <content styleCode="bold">
                        <sup>TM
</sup>
                     </content>
                     <content styleCode="bold">(ahm-voh)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(mirikizumab-mrkz)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">injection, for subcutaneous use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Prefilled Pens</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">One 200 mg/2 mL Prefilled Pen and one 100 mg/mL Prefilled Pen for a full dose of 300 mg</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="76.150%" align="left"/>
                     <col width="23.850%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f13" referencedObject="mm13"/>
                           </td>
                           <td align="center" valign="bottom">
                              <renderMultiMedia ID="f14" referencedObject="mm14"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">This Instructions for Use contains information on how to inject OMVOH.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you use the OMVOH prefilled Pens, read and carefully follow all the step-by-step instructions.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before injecting OMVOH</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 OMVOH injections, using the provided 100 mg/mL and 200 mg/2 mL prefilled Pens, are required for a full 300 mg dose.
</item>
                                 <item>The prefilled Pens may be used in any order.
</item>
                                 <item>Inject 1 OMVOH prefilled Pen followed right away by the other OMVOH prefilled Pen.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="Disc">
                     <item>Your healthcare provider should show you how to prepare and inject OMVOH using the prefilled Pens. <content styleCode="bold">Do not</content> inject yourself or someone else until you have been shown how to inject OMVOH.
</item>
                     <item>Keep this Instructions for Use and read it as needed.
</item>
                     <item>Each OMVOH prefilled Pen is for <content styleCode="bold">one-time use only.</content>
                     </item>
                     <item>The OMVOH prefilled Pen contains glass parts. Handle it carefully. If you drop it on a hard surface, <content styleCode="bold">do not</content> use it. Use a new OMVOH prefilled Pen for your injection.
</item>
                     <item>Your healthcare provider can help you decide where on your body to inject your dose. Read the <content styleCode="bold">Choose and clean your injection sites</content> section of these instructions to help you choose which area can work best for you.
</item>
                     <item>If you have vision or hearing problems, <content styleCode="bold">do not</content> use OMVOH prefilled Pens without help from a caregiver.
</item>
                     <item>See <content styleCode="bold">
									Storing OMVOH Prefilled Pens
								</content> for important storage information.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>Before you use the OMVOH prefilled Pens, read and carefully follow all the step-by-step instructions.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 Prefilled Pens = full 300 mg dose</content>
                  </paragraph>
                  <paragraph>After your first injection, <content styleCode="bold">choose</content> a new injection site at least 2 inches (5 centimeters) away and clean it.
</paragraph>
                  <paragraph>With your second prefilled Pen<content styleCode="bold">, repeat steps 1 to 3</content> right away after your first injection.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">You must inject 2 prefilled Pens to complete your full 300 mg dose.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Parts of the OMVOH Prefilled Pens</content>
                  </paragraph>
                  <paragraph>Inject both prefilled Pens in any order for a full 300 mg dose.
</paragraph>
                  <paragraph>The 200 mg/2 mL prefilled Pen is larger than the 100 mg/mL prefilled Pen.
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f15" referencedObject="mm15"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Preparing to inject OMVOH</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Gather supplies</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.000%" align="left"/>
                     <col width="50.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>a carton containing 2 OMVOH prefilled Pens from the refrigerator
</item>
                                 <item>2 alcohol wipes
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 cotton balls
</item>
                                 <item>sharps disposal container
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Inspect the prefilled Pens and the medicine</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Remove both prefilled Pens</content> from the carton.
</paragraph>
                  <paragraph>Make sure you have the right medicine.
</paragraph>
                  <paragraph>The medicine inside should be clear. It may be colorless to slightly yellow to slightly brown.
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="25.000%" align="left"/>
                     <col width="75.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="bottom">
                              <br/>
                              <renderMultiMedia ID="f16" referencedObject="mm16"/>
                           </td>
                           <td align="left" valign="middle">
                              <content styleCode="bold">Do not</content> use the prefilled Pens (see <content styleCode="bold">Throwing away (disposing of) OMVOH Prefilled Pens</content>) if:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>one or both prefilled Pens looks damaged
</item>
                                 <item>the medicine is cloudy, discolored, or has particles
</item>
                                 <item>the expiration date printed on the label has passed
</item>
                                 <item>the medicine is or has been frozen.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Wait 45 minutes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> warm up the prefilled Pens with a microwave, hot water, or direct sunlight.
</paragraph>
                  <paragraph>With the gray base cap on, allow the prefilled Pens to warm up to room temperature for 45 minutes before injecting.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Choose and clean your injection sites</content>
                  </paragraph>
                  <paragraph>Your healthcare provider can help you choose the injection sites that are best for you. <content styleCode="bold">Clean the injection sites with an alcohol wipe and let them dry.</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="18.333%" align="left"/>
                     <col width="20.833%" align="left"/>
                     <col width="60.833%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f17" referencedObject="mm17"/>
                           </td>
                           <td align="left" valign="middle">You or another person may inject into these areas.
</td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> inject into areas where the skin is tender, bruised, red, or hard.<br/>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Stomach area (abdomen)<br/>
                                    </content>At least 2 inches away from the belly button (navel).<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Front of thigh<br/>
                                    </content>At least 2 inches above the knee and 2 inches below the groin.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f18" referencedObject="mm18"/>
                           </td>
                           <td align="left" valign="middle">Another person should inject into this area.
</td>
                           <td align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Back of upper arm<br/>
                                    </content>Another person should inject into the back of your upper arm.
</item>
                              </list>
                              <content styleCode="bold">Injections should be at least 2 inches apart.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Injecting OMVOH</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1. Uncap the first prefilled Pen (the prefilled Pens may be used in any order)</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="32.175%" align="left"/>
                     <col width="8.925%" align="left"/>
                     <col width="29.450%" align="left"/>
                     <col width="29.450%" align="left"/>
                     <tbody>
                        <tr>
                           <td rowspan="2" align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f19" referencedObject="mm19"/>
                           </td>
                           <td align="left" valign="bottom">
                              <br/>
                              <renderMultiMedia ID="f20" referencedObject="mm20"/>
                           </td>
                           <td align="left" valign="bottom">Make sure the prefilled Pen is <content styleCode="bold">locked</content>.
</td>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f21" referencedObject="mm21"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top"/>
                           <td colspan="2" align="left" valign="middle">
                              <content styleCode="bold">Twist off</content> the gray base cap and <content styleCode="bold">throw the cap away</content> in the trash when you are ready to inject.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> put the gray base cap back on –<br/>this could damage the needle.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> touch the needle inside the clear base.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">2. Place and unlock</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="36.633%" align="left"/>
                     <col width="8.933%" align="left"/>
                     <col width="54.433%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f22" referencedObject="mm22"/>
                           </td>
                           <td align="left" valign="middle">
                              <br/>
                              <br/>
                              <br/>
                              <br/>
                              <renderMultiMedia ID="f23" referencedObject="mm23"/>
                           </td>
                           <td align="left" valign="middle">
                              <content styleCode="bold">Place</content> and hold the clear base flat against the skin.<br/>
                              <br/>Keep the clear base on the skin, then turn the lock ring to the <content styleCode="bold">unlock</content> position.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">3. Press and hold for 15 seconds</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="42.567%" align="left"/>
                     <col width="29.933%" align="left"/>
                     <col width="27.500%" align="left"/>
                     <tbody>
                        <tr>
                           <td rowspan="3" align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f24" referencedObject="mm24"/>
                           </td>
                           <td colspan="2" align="left" valign="top">
                              <content styleCode="bold">Press and Hold</content> the blue injection button and <content styleCode="bold">listen</content> for 2 loud clicks:<br/>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>first click = injection started
</item>
                                 <item>second click = injection completed<br/>The injection may take up to 15 seconds.<br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="middle">You will know the injection is complete when the gray plunger is visible.
</td>
                           <td align="left" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f25" referencedObject="mm25"/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle">Remove the prefilled Pen from the skin.<br/>
                              <br/>If you have bleeding at the injection site, press a cotton ball over the injection site.<br/>
                              <content styleCode="bold">Do not</content> rub the injection site.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">4. Inject the second prefilled Pen</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Choose</content> a new injection site at least 2 inches away and clean it.
</paragraph>
                  <paragraph>With your second prefilled Pen, <content styleCode="bold">repeat steps 1 to 3</content> right away after your first injection.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">You must inject 2 prefilled Pens to complete your full 300 mg dose.</content>
                  </paragraph>
                  <paragraph ID="p05">
                     <content styleCode="bold">Throwing away (disposing of) OMVOH Prefilled Pens</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Throw away both used prefilled Pens</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="40.850%" align="left"/>
                     <col width="59.150%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f26" referencedObject="mm26"/>
                           </td>
                           <td align="left" valign="middle">Put the used OMVOH prefilled Pens in an FDA-cleared sharps disposal container right away after use.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> throw away (dispose of) the OMVOH prefilled Pens in your household trash.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> recycle your sharps disposal container.<br/>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle">
                              <br/>For more information, see <content styleCode="bold">Used OMVOH prefilled Pen disposal.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p04">
                     <content styleCode="bold">Storing OMVOH Prefilled Pens</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Refrigeration</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>In the original carton, store your prefilled pens in the refrigerator between 36°F to 46°F (2°C to 8°C) until the expiration date.
</item>
                     <item>Do not freeze. Do not use OMVOH if it has been frozen.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Room Temperature</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>If needed, your prefilled Pens may be stored at room temperature for up to 2 weeks in the original carton. <content styleCode="bold">Do not</content> store above 86°F (30°C).
</item>
                     <item>When OMVOH has been stored at room temperature, do not return it to the refrigerator.
</item>
                     <item>Throw away (dispose of) OMVOH if not used within 2 weeks at room temperature.
</item>
                     <item>Protect your prefilled Pens from light until use.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Do not</content> use the prefilled Pens and throw away (see <content styleCode="bold">
								Throwing away (disposing of) OMVOH Prefilled Pens</content>) if they have been:
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.000%" align="left"/>
                     <col width="50.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>frozen
</item>
                                 <item>microwaved
</item>
                                 <item>warmed with hot water
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>left in direct sunlight
</item>
                                 <item>shaken
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Keep OMVOH and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Commonly asked questions</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="5.700%" align="left"/>
                     <col width="94.300%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">The prefilled Pens are different sizes. Should I take one before the other?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">You can inject the prefilled Pens in any order. Inject both prefilled Pens for a full 300 mg dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if I see air bubbles in the prefilled Pens?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">Air bubbles are normal. They will not harm you or affect your dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid on the tip of the needle when I remove the gray base cap?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">A drop of liquid on the tip of the needle is normal. This will not harm you or affect your dose. <content styleCode="bold">Do not</content> touch the needle.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if I unlock the prefilled Pen and press the blue injection button before twisting off the gray base cap?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">Do not remove the gray base cap. Throw away (dispose of) the prefilled Pen and get a new one.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do I need to hold the blue injection button down until the injection is complete?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">You do not need to hold the blue injection button down, but it may help you keep the prefilled Pen steady against your skin.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if the needle did not retract after my injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> touch the needle or replace the gray base cap. Store the prefilled Pen in a safe place to avoid an accidental needlestick and contact 1-800-Lilly-Rx (1-800-545-5979) for instructions on how to return the prefilled Pen.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid or blood on my skin after my injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">This is normal. Press a cotton ball over the injection site. <content styleCode="bold">Do not</content> rub the injection site.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">How can I tell if my injection is complete?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">After you press the blue injection button, you will hear 2 loud clicks. The second loud click tells you that your injection is complete. You will also see the gray plunger at the top of the clear base. The injection may take up to 15 seconds.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if I remove the prefilled Pen before the second loud click or before the gray plunger stops moving?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">You may not have received your full dose. <content styleCode="bold">Do not</content> give another injection. Call your healthcare provider for help.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if I heard more than 2 clicks during my injection – 2 loud clicks and 1 soft one. Did I get my complete injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">Some people may hear a soft click right before the second loud click. That is the normal operation of the prefilled Pen. <content styleCode="bold">Do not</content> remove the prefilled Pen from your skin until you hear the second loud click.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Additional Information:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you have more questions about how to use the OMVOH prefilled Pens:</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="40.833%" align="left"/>
                     <col width="20.833%" align="left"/>
                     <col width="38.333%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Call your healthcare provider
</item>
                                 <item>Call 1-800-Lilly-Rx (1-800-545-5979)
</item>
                                 <item>Visit www.OMVOH.com<br/>
                                 </item>
                              </list>
                           </td>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f27" referencedObject="mm27"/>
                           </td>
                           <td align="left" valign="middle">Scan this code to launch www.OMVOH.COM
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p07">
                     <content styleCode="bold">Used OMVOH Prefilled Pen disposal</content>
                  </paragraph>
                  <paragraph>Put the used OMVOH prefilled Pens in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the OMVOH prefilled Pens in your household trash.
</paragraph>
                  <paragraph>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>made of a heavy-duty plastic,
</item>
                     <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                     <item>upright and stable during use,
</item>
                     <item>leak-resistant, and
</item>
                     <item>properly labeled to warn of hazardous waste inside the container.
</item>
                  </list>
                  <paragraph>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container.
</paragraph>
                  <paragraph>There may be state or local laws about how you should throw away needles and syringes.
</paragraph>
                  <paragraph>For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read the Medication Guide for OMVOH inside this box to learn more about your medicine.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:<br/>Eli Lilly and Company<br/>Indianapolis, IN 46285, USA<br/>US License Number 1891</content>
                  </paragraph>
                  <paragraph>OMVOH<sup>TM</sup> is a trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright © 2025, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. Approved: January 2025
</paragraph>
                  <paragraph>The OMVOH prefilled Pen meets the current dose accuracy and functional requirements of ISO 11608-1 and 11608-5.
</paragraph>
                  <paragraph>OMV-0001-300MG-PEN-IFU-20250115
</paragraph>
               </text>
               <effectiveTime value="20250115"/>
               <component>
                  <observationMedia ID="mm13">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-1-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm14">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm15">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-2-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm16">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-3-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm17">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-ifu-injection-sites-front-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm18">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-ifu-injection-sites-back-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm19">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-4-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm20">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-ai-lock.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm21">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-5-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm22">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-6-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm23">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-ai-unlock.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm24">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-7-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm25">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-8-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm26">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pen-9-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm27">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-qr-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s87">
               <id root="14da1d5b-b11f-44b8-9705-4c8ca028d42d"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Omvoh 300 mg Dose Prefilled Syringe Instructions for Use - Crohns Disease </title>
               <text>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">OMVOH</content>
                     <content styleCode="bold">
                        <sup>TM
</sup>
                     </content>
                     <content styleCode="bold">(ahm-voh)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(mirikizumab-mrkz)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">injection, for subcutaneous use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">One 200 mg/2 mL (100 mg/mL) Prefilled Syringe and One 100 mg/mL Prefilled Syringe for a Full Dose of 300 mg.</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="78.600%" align="left"/>
                     <col width="21.400%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f38" referencedObject="mm38"/>
                           </td>
                           <td align="center" valign="bottom">
                              <renderMultiMedia ID="f39" referencedObject="mm39"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">This Instructions for Use contains information on how to inject OMVOH.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you use the OMVOH prefilled Syringes, read and carefully follow all the step-by-step instructions.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before injecting OMVOH</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 OMVOH injections, using the provided 100 mg/mL and 200 mg/2 mL (100 mg/mL) prefilled Syringes, are required for a full 300 mg dose.
</item>
                                 <item>The prefilled Syringes may be used in any order.
</item>
                                 <item>Inject 1 OMVOH prefilled Syringe followed right away by the other OMVOH prefilled Syringe.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="Disc">
                     <item>Your healthcare provider should show you how to prepare and inject OMVOH using the prefilled Syringes. <content styleCode="bold">Do not</content> inject yourself or someone else until you have been shown how to inject OMVOH.
</item>
                     <item>Keep this Instructions for Use and read it as needed.
</item>
                     <item>Each OMVOH prefilled Syringe is for <content styleCode="bold">one-time use only.</content>
                     </item>
                     <item>Your healthcare provider can help you decide where on your body to inject your dose. Read the <content styleCode="bold">Choose and clean your injection sites</content> section of these instructions to help you choose which area can work best for you.
</item>
                     <item>If you have vision problems, <content styleCode="bold">do not</content> use OMVOH prefilled Syringes without help from a caregiver.
</item>
                     <item>See <content styleCode="bold">
									Storing OMVOH prefilled Syringes
								</content> for important storage information.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>Before you use the OMVOH prefilled Syringes, read and carefully follow all the step-by-step instructions.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">2 Prefilled Syringes = full 300 mg dose</content>
                  </paragraph>
                  <paragraph>After your first injection, <content styleCode="bold">choose</content> a new injection site at least 2 inches away and clean it.
</paragraph>
                  <paragraph>With your second prefilled Syringe<content styleCode="bold">, repeat steps 1 to 3</content> right away after your first injection.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">You must inject 2 prefilled Syringes to complete your full 300 mg dose.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Parts of the OMVOH prefilled Syringes</content>
                  </paragraph>
                  <paragraph>Inject both prefilled Syringes in any order for a full 300 mg dose.
</paragraph>
                  <paragraph>The 200 mg/2 mL (100 mg/mL) prefilled Syringe is larger than the 100 mg/mL prefilled Syringe.
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f40" referencedObject="mm40"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Preparing to inject OMVOH</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Gather supplies</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.000%" align="left"/>
                     <col width="50.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>a carton containing 2 OMVOH prefilled Syringes from the refrigerator
</item>
                                 <item>2 alcohol wipes
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>2 cotton balls
</item>
                                 <item>sharps disposal container
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Inspect the prefilled Syringes and the medicine</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Remove both prefilled Syringes</content> from the carton.
</paragraph>
                  <paragraph>Make sure you have the right medicine.
</paragraph>
                  <paragraph>The medicine inside should be clear. It may be colorless to slightly yellow to slightly brown.
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="44.300%" align="left"/>
                     <col width="55.700%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f41" referencedObject="mm41"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> use the prefilled Syringes (see <content styleCode="bold">
											Throwing away (disposing of) OMVOH Prefilled Syringes</content>) if:
											<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>one or both prefilled Syringes looks damaged
</item>
                                 <item>the medicine is cloudy, discolored, or has particles
</item>
                                 <item>the expiration date printed on the label has passed
</item>
                                 <item>the medicine is or has been frozen.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Wait 45 minutes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> warm up the prefilled Syringes with a microwave, hot water, or direct sunlight.
</paragraph>
                  <paragraph>With the needle cap on, allow the prefilled Syringes to warm up to room temperature for 45 minutes before injecting.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Choose and clean your injection sites</content>
                  </paragraph>
                  <paragraph>Your healthcare provider can help you choose the injection sites that are best for you. <content styleCode="bold">Clean the injection sites with an alcohol wipe and let them dry.</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="18.333%" align="left"/>
                     <col width="20.833%" align="left"/>
                     <col width="60.833%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f42" referencedObject="mm42"/>
                           </td>
                           <td align="left" valign="middle">You or another person may inject into these areas.
</td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Do not</content> inject into areas where the skin is tender, bruised, red, or hard.<br/>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Stomach area (abdomen)<br/>
                                    </content>At least 2 inches away from the belly button (navel).
</item>
                                 <item>
                                    <content styleCode="bold">Front of thigh<br/>
                                    </content>At least 2 inches above the knee and 2 inches below the groin.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f43" referencedObject="mm43"/>
                           </td>
                           <td align="left" valign="middle">Another person should inject into this area.
</td>
                           <td align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Back of upper arm<br/>
                                    </content>Another person should inject into the back of your upper arm.
</item>
                              </list>
                              <content styleCode="bold">Injections should be at least 2 inches apart.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Injecting OMVOH</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">1. Uncap the first prefilled Syringe (the prefilled Syringes may be used in any order)</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="38.450%" align="left"/>
                     <col width="61.550%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <br/>
                              <renderMultiMedia ID="f44" referencedObject="mm44"/>
                           </td>
                           <td align="left" valign="middle">
                              <content styleCode="bold">Hold the prefilled syringe body</content> and <content styleCode="bold">pull off</content> the needle cap when you are ready to inject. <content styleCode="bold">Throw away</content> the needle cap in the trash.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> put the needle cap back on —<br/>this could damage the needle.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> touch the needle.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">2. Pinch the injection site and insert the needle</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="38.450%" align="left"/>
                     <col width="61.550%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="middle">
                              <br/>
                              <renderMultiMedia ID="f45" referencedObject="mm45"/>
                           </td>
                           <td align="left" valign="middle">Gently <content styleCode="bold">pinch and hold</content> a fold of skin where you will inject.<br/>
                              <br/>
                              <content styleCode="bold">Insert</content> the needle at a 45-degree angle.<br/>
                              <br/>Gently <content styleCode="bold">let go</content> of the skin while keeping the needle in place.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">3. Inject the medicine</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="16.728%" align="left"/>
                     <col width="27.224%" align="left"/>
                     <col width="56.048%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f46" referencedObject="mm46"/>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">Slowly push</content> on the thumb pad to push the blue plunger rod all the way in until all the medicine is injected.<br/>
                              <br/>The gray syringe plunger should be pushed all the way to the needle end of the prefilled Syringe.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <br/>
                              <renderMultiMedia ID="f47" referencedObject="mm47"/>
                           </td>
                           <td align="left" valign="top"/>
                           <td align="left" valign="middle">You should see the blue plunger rod show through the prefilled Syringe body when the injection is complete as shown.<br/>
                              <br/>Remove the needle from your skin.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> put the needle cap back on the prefilled Syringe.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top">If you have bleeding at the injection site, press a cotton ball over the injection site. <content styleCode="bold">Do not</content> rub the injection site.
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">4. Inject the second prefilled Syringe</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Choose</content> a new injection site at least 2 inches away and clean it.
</paragraph>
                  <paragraph>With your second prefilled Syringe, <content styleCode="bold">repeat steps 1 to 3</content> right away after your first injection.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">You must inject 2 prefilled Syringes to complete your full 300 mg dose.</content>
                  </paragraph>
                  <paragraph ID="p11">
                     <content styleCode="bold">Throwing away (disposing of) OMVOH Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Throw away both used prefilled Syringes</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="25.850%" align="left"/>
                     <col width="74.150%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f48" referencedObject="mm48"/>
                           </td>
                           <td align="left" valign="top">Put the used OMVOH prefilled Syringes in an FDA-cleared sharps disposal container right away after use.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> throw away (dispose of) the OMVOH prefilled Syringes in your household trash.<br/>
                              <br/>
                              <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</td>
                        </tr>
                        <tr>
                           <td colspan="2" align="left" valign="middle">For more information, see <content styleCode="bold">Used OMVOH prefilled Syringe disposal.</content>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p10">
                     <content styleCode="bold">Storing OMVOH Prefilled Syringes</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Refrigeration</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>In the original carton, store your prefilled Syringes in the refrigerator between 36°F to 46°F (2°C to 8°C) until the expiration date.
</item>
                     <item>
                        <content styleCode="bold">Do not</content> freeze. <content styleCode="bold">Do not</content> use OMVOH if it has been frozen.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Room Temperature</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>If needed, your prefilled Syringes may be stored at room temperature for up to 2 weeks in the original carton. <content styleCode="bold">Do not</content> store above 86°F (30°C).
</item>
                     <item>When OMVOH has been stored at room temperature, do not return it to the refrigerator.
</item>
                     <item>Throw away (dispose of) OMVOH if not used within 2 weeks at room temperature.
</item>
                     <item>Protect your prefilled Syringes from light until use.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Do not</content> use the prefilled Syringes and throw away (see <content styleCode="bold">
								Throwing away (disposing of) OMVOH Prefilled Syringes</content>) if they have been:
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.000%" align="left"/>
                     <col width="50.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="bottom">
                              <list listType="unordered" styleCode="Disc">
                                 <item>frozen
</item>
                                 <item>microwaved
</item>
                                 <item>warmed with hot water
</item>
                              </list>
                           </td>
                           <td align="left" valign="bottom">
                              <list listType="unordered" styleCode="Disc">
                                 <item>left in direct sunlight
</item>
                                 <item>shaken
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Keep OMVOH and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Commonly asked questions</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="5.700%" align="left"/>
                     <col width="94.300%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">The prefilled Syringes are different sizes. Should I take one before the other?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">You can inject the prefilled Syringes in any order. Inject both prefilled Syringes for a full 300 mg dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if I see air bubbles in the prefilled Syringes?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">Air bubbles are normal. They will not harm you or affect your dose.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">A drop of liquid on the tip of the needle is normal. This will not harm you or affect your dose. <content styleCode="bold">Do not</content> touch the needle.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if I cannot push in the plunger?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">If the plunger is stuck or damaged:<list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> continue to use the prefilled Syringe
</item>
                                 <item>Remove the needle from your skin
</item>
                                 <item>Dispose of the prefilled Syringe and get a new one
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">What if there is a drop of liquid or blood on my skin after my injection?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">This is normal. Press a cotton ball over the injection site. <content styleCode="bold">Do not</content> rub the injection site.
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Q.</content>
                           </td>
                           <td align="left" valign="top">
                              <content styleCode="bold">How can I tell if my injection is complete?</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">A.
</td>
                           <td align="left" valign="top">When your injection is complete:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>The blue plunger rod should show through the body of the prefilled Syringe.
</item>
                                 <item>The gray syringe plunger should be pushed all the way to the needle end of the prefilled Syringe.
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Additional Information:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">If you have more questions about how to use the OMVOH prefilled Syringes:</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="40.833%" align="left"/>
                     <col width="20.833%" align="left"/>
                     <col width="38.333%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="middle">
                              <list listType="unordered" styleCode="Disc">
                                 <item>Call your healthcare provider
</item>
                                 <item>Call 1-800-Lilly-Rx (1-800-545-5979)
</item>
                                 <item>Visit www.OMVOH.com<br/>
                                 </item>
                              </list>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f49" referencedObject="mm49"/>
                           </td>
                           <td align="left" valign="middle">Scan this code to launch www.OMVOH.COM
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p12">
                     <content styleCode="bold">Used OMVOH Prefilled Syringe disposal</content>
                  </paragraph>
                  <paragraph>Put the used OMVOH prefilled Syringes in an FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not</content> throw away (dispose of) the OMVOH prefilled Syringes in your household trash.
</paragraph>
                  <paragraph>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>made of a heavy-duty plastic,
</item>
                     <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                     <item>upright and stable during use,
</item>
                     <item>leak-resistant, and
</item>
                     <item>properly labeled to warn of hazardous waste inside the container.
</item>
                  </list>
                  <paragraph>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container.
</paragraph>
                  <paragraph>There may be state or local laws about how you should throw away needles and syringes.
</paragraph>
                  <paragraph>For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not</content> recycle your used sharps disposal container.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Read the Medication Guide for OMVOH inside this box to learn more about your medicine.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured by:<br/>Eli Lilly and Company<br/>Indianapolis, IN 46285, USA<br/>US License Number 1891</content>
                  </paragraph>
                  <paragraph>OMVOH<sup>TM</sup> is a trademark of Eli Lilly and Company.
</paragraph>
                  <paragraph>Copyright © 2025, Eli Lilly and Company. All rights reserved.
</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.
</paragraph>
                  <paragraph>Approved: January 2025
</paragraph>
                  <paragraph>OMV-0001-300MG-PFS-IFU-20250115
</paragraph>
               </text>
               <effectiveTime value="20250115"/>
               <component>
                  <observationMedia ID="mm38">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pfs-1-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm39">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="logo.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm40">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pfs-2-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm41">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pfs-3-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm42">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-ifu-injection-sites-front-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm43">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-ifu-injection-sites-back-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm44">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pfs-4-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm45">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-100mg-pfs-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm46">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pfs-6-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm47">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pfs-7-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm48">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-300mg-pfs-8-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm49">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-qr-v1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s88">
               <id root="5cd238ad-257d-4961-a6cb-9de2757b9a22"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – Omvoh 300 mg Vial Carton</content>
                  </paragraph>
                  <paragraph>NDC 0002-7575-01
</paragraph>
                  <paragraph>15 mL
</paragraph>
                  <paragraph>omvoh<sup>TM</sup>
                  </paragraph>
                  <paragraph>(mirikizumab-mrkz)
</paragraph>
                  <paragraph>injection
</paragraph>
                  <paragraph>300 mg/15 mL
</paragraph>
                  <paragraph>(20 mg/mL)
</paragraph>
                  <paragraph>For Intravenous Infusion After Dilution
</paragraph>
                  <paragraph>Single-Dose Vial - Discard Unused Portion
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>omvoh.com
</paragraph>
                  <paragraph>Lilly
</paragraph>
                  <renderMultiMedia ID="f50" referencedObject="mm50"/>
               </text>
               <effectiveTime value="20250115"/>
               <component>
                  <observationMedia ID="mm50">
                     <text>PACKAGE LABEL – Omvoh 300 mg Vial Carton
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-carton-300mg-vial-049-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s89">
               <id root="fcc2f9fc-b422-476b-9431-17d3ebf811b6"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – Omvoh Prefilled Pen 200 mg Dose Carton - Ulcerative Colitis</content>
                  </paragraph>
                  <paragraph>NDC 0002-8011-27
</paragraph>
                  <paragraph>omvoh<sup>TM</sup>
                  </paragraph>
                  <paragraph>(mirikizumab-mrkz)
									 <br/> injection
</paragraph>
                  <paragraph>100 mg/mL
</paragraph>
                  <paragraph>For Subcutaneous Use Only
</paragraph>
                  <paragraph>This carton contains a total dose of 200 mg. <br/> Inject both prefilled pens one after the other for a full dose of 200 mg. 
</paragraph>
                  <paragraph>Note to Pharmacist: The entire carton is to be dispensed as a unit. </paragraph>
                  <paragraph>2 x 1 mL single-dose prefilled pens
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly 
</paragraph>
                  <renderMultiMedia ID="f51" referencedObject="mm51"/>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="mm51">
                     <text>PACKAGE LABEL – Omvoh 100 mg Prefilled Pen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-carton-100mg-pen-078-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s90">
               <id root="f16127b6-3f63-4cbe-8aff-d24c676889d0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – Omvoh Prefilled Syringe 200 mg Dose Carton - Ulcerative Colitis</content>
                  </paragraph>
                  <paragraph>NDC 0002-8870-27
</paragraph>
                  <paragraph>omvoh<sup>TM</sup>
                  </paragraph>
                  <paragraph>(mirikizumab-mrkz) <br/>injection
</paragraph>
                  <paragraph>100 mg/mL
</paragraph>
                  <paragraph>For Subcutaneous Use Only
</paragraph>
                  <paragraph>Note to Pharmacist: The entire carton is to be dispensed as a unit.
</paragraph>
                  <paragraph>This carton contains a total dose of 200 mg. <br/> Inject both prefilled syringes one after the other for a full dose of 200 mg.</paragraph>
                  <paragraph>2 x 1 mL single-dose prefilled syringes
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly 
</paragraph>
                  <renderMultiMedia ID="f52" referencedObject="mm52"/>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="mm52">
                     <text>PACKAGE LABEL – Omvoh 100 mg Prefilled Syringe
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-carton-100mg-pfs-100-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s91">
               <id root="84ff84d3-ec19-4f40-b252-d585945263ac"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – Omvoh Prefilled Pen 300 mg Dose Carton - Crohns Disease</content>
                  </paragraph>
                  <paragraph>NDC 0002-7717-11
</paragraph>
                  <paragraph>omvoh<sup>TM</sup>
                  </paragraph>
                  <paragraph>(mirikizumab-mrkz) <br/> injection
</paragraph>
                  <paragraph>200 mg/2 mL <br/>100 mg/mL
</paragraph>
                  <paragraph>For Subcutaneous Use Only
</paragraph>
                  <paragraph>Note to Pharmacist: The entire carton is to be dispensed as a unit. 
</paragraph>
                  <paragraph>This carton contains a total dose of 300 mg. <br/> Inject both prefilled pens one after the other for a full dose of 300 mg. 
</paragraph>
                  <paragraph>See full storage conditions on carton bottom. 
</paragraph>
                  <paragraph>1 x 2 mL single-dose prefilled pen <br/>1 x 1 mL single-dose prefilled pen
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly 
</paragraph>
                  <renderMultiMedia ID="f54" referencedObject="mm54"/>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="mm54">
                     <text>PACKAGE LABEL – Omvoh 300 mg Prefilled Pen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-carton-300mg-pen-109-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s92">
               <id root="563b1f70-e0fe-4590-83d6-cd6cae35695d"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – Omvoh Prefilled Syringe 300 mg Dose Carton - Crohns Disease</content>
                  </paragraph>
                  <paragraph>NDC 0002-7722-11
</paragraph>
                  <paragraph>omvoh<sup>TM</sup>
                  </paragraph>
                  <paragraph>(mirikizumab-mrkz) <br/> injection
</paragraph>
                  <paragraph>200 mg/2 mL <br/> (100 mg/mL) <br/> 100 mg/mL
</paragraph>
                  <paragraph>For Subcutaneous Use Only
</paragraph>
                  <paragraph>Note to Pharmacist: This entire carton is to be dispensed as a unit. 
</paragraph>
                  <paragraph>This carton contains a total dose of 300 mg. <br/> Inject both prefilled syringes one after the other for a full dose of 300 mg. 
</paragraph>
                  <paragraph>1 x 2 mL single-dose prefilled syringe <br/>1 x 1 mL single-dose prefilled syringe
</paragraph>
                  <paragraph>Rx only
</paragraph>
                  <paragraph>Dispense enclosed Medication Guide to each patient.
</paragraph>
                  <paragraph>Lilly 
</paragraph>
                  <renderMultiMedia ID="f53" referencedObject="mm53"/>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="mm53">
                     <text>PACKAGE LABEL – Omvoh 300 mg Prefilled Syringe
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="omvoh-carton-300mg-pfs-107-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s93">
               <id root="dbdfab25-6936-43c8-8660-d0cbf9046267"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL – Omvoh Prefilled Pen 200 mg </content>
                  </paragraph>
                  <paragraph>NDC 0002-3116-02
</paragraph>
                  <paragraph>Image Not Available</paragraph>
                  <renderMultiMedia ID="f55" referencedObject="mm55"/>
               </text>
               <effectiveTime value="20250403"/>
               <component>
                  <observationMedia ID="mm55">
                     <text>PACKAGE LABEL – Omvoh 200 mg Prefilled Pen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="PDP-Image-Placeholder.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>